An Open- Label, Parallel -Group, Controlled Study to Evaluate Changes in Biomarkers of 
Cigarette Smoke Exposure and Biomarkers of Potential Harm in Adult Smokers Who 
Completely Switch to Using e- Vapor Products for 12 Weeks  
[STUDY_ID_REMOVED]  
10NOV2016  
Altria Client Services Study No. ALCS-RA-16-06-EV 
An Open-Label, Randomized, Parallel-Group, Controlled Study to Evaluate Changes in Biomarkers 
of Cigarette Smoke Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely 
Switch to Using e-Vapor Products for 12 Weeks 
Sponsor: 
Medical Monitor: Altria Client Services Study No. ALCS-RA-16-06-EV 
Final Protocol Date: [ADDRESS_591338] 
Richmond, Virginia [ZIP_CODE] 
 
 
 
 
The information contained herein is confidential and the proprietary property of Altria Client Services 
LLC and any unauthorized use or disclosure of such info1mation without the prior written authorization 
of Altria Client Services LLC is expressly prohibited. 
Page 1 of 110 HIGHL Y CONFIDENTIAL 
VERSION: Final Date 10 November 2016 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 2 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  An Open-Label, Randomized, Parallel-Group, Controlled Study to Evaluate Changes in Biomarkers 
of Cigarette Smoke Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely 
Switch to Using e-Vapor Products for 12 Weeks   
Altria
 Client Services Study No. ALCS-RA-16-06 -EV  
 
 
Sponsor’s Contact:   
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
 
 

[CONTACT_461951]. ALCS- RA-16-06-EV  
 
 
Page 3 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591339] be approved by [CONTACT_461952] (ALCS) prior to seeking approval from the 
Institutional Review Board (IRB). 
This study will be conducted in accordance with Good Clinical Practice (GCP) based on the current 
International Conference on Harmonization (ICH) guidelines for GCP and the corresponding sections of the 
[LOCATION_002] (US) Code of Federal Regulations (CFR) governing Protection of Human Subjects (Title 
21 CFR Part 50), Institutional Review Boards (Title 21 CFR Part 56), the Basic Principles of the 
De
claration of Helsinki, and applicable legal and regulatory requirements. 
Principal Investigator:   
 
 
 
 
[CONTACT_7626]:  
Fax: 
E-mail:   
 
 
 
 
 (Signature)  (Date)  
  
 
 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 4 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  TABLE OF CONTENTS 
 
Page 
 
STUDY SYNOPSIS .............................................................................................................................................  10 
SUMMARY OF EVENTS/ASSESSMENTS ....................................................................................................... [ADDRESS_591340] e-Vapor Products ............................................................................................................  44 
5.3.2  Conventional Cigarettes ......................................................................................................... 45 
6.0 VISIT 1, SCREENING PART 1 (DAY -28 TO DAY - 7)................................................................... 45 
 Age Verification and Photocopy of ID ................................................................................................... 45 6.1
 Informed Consent ................................................................................................................................... 45 6.2
 Medical History ...................................................................................................................................... 45 6.3
 Demographics and Tobacco Use History Questionnaires ...................................................................... 46 6.4
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 5 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Review Inclusion / Exclusion Criteria .................................................................................................... [ADDRESS_591341] (Females) ..........................................................................................  48 
 Review of Concomitant Medications ..................................................................................................... 48 6.10
 Review of Tobacco and Nicotine Restrictions .......................................................................................  48 6.11
7.0 VISIT 2, SCEENING PART 2 (AFTER ASSESSMENT OF SCREENING PART 1 AND ON OR BEFORE 
DAY -5) ..................................................................................................................................................  48 
 Review Inclusion / Exclusion Criteria .................................................................................................... [ADDRESS_591342] .............................................................................................................................  49 7.5
 Spi[INVESTIGATOR_038] ..............................................................................................................................................  49 7.6
 Review of Concomitant Medications ..................................................................................................... 49 7.7
 Confirm Cigarette Brand / Photocopy Cigarette Pack ............................................................................  [ADDRESS_591343] Urine Void Collection Containers ..................................................................................  51 7.14
 Reminder Calls ....................................................................................................................................... 51 7.15
8.0 VISIT 3, BASELINE, RANDOMIZATION (DAY 1) ....................................................................... 51 
 Review of Inclusion / Exclusion Criteria ................................................................................................  51 8.1
 Vital Signs ..............................................................................................................................................  52 8.2
 Body Weight and Body Mass Index ....................................................................................................... 52 8.3
 Physical Examination (Symptom Driven) ..............................................................................................  [ADDRESS_591344] .............................................................................................................................  52 8.5
 Review of Concomitant Medications ..................................................................................................... 52 8.6
 Review of Tobacco and Nicotine Restrictions .......................................................................................  52 8.7
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 6 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Review of Adverse Events .....................................................................................................................  53 8.8
 Confirm Cigarette Brand / Photocopy Cigarette Pack ............................................................................  53 8.9
 QGEN and TQOLIT questionnaires (before product use – Day 1 only) ................................................  53 8.10
 Cough Questionnaire (before product use – Day 1 only) ....................................................................... [ADDRESS_591345] Use .................................................................. 55 8.16
 Exhaled CO Measurement ......................................................................................................................  55 8.17
 BOE and BOPH Urine Sample Collection (before randomization) .......................................................  55 8.18
9.0 VISIT 4 (WEEK 3 / DAY 21 ± 3) ........................................................................................................ 55 
 Review of Inclusion / Exclusion Criteria ................................................................................................  56 9.1
 Vital Signs ..............................................................................................................................................  56 9.2
 Review of Concomitant Medications ..................................................................................................... 56 9.3
 Review of Tobacco and Nicotine Restrictions .......................................................................................  56 9.4
 Review of Adverse Events .....................................................................................................................  56 9.5
 Confirm Regular Cigarette Brand / Photocopy Cigarette Pack ..............................................................  [ADDRESS_591346] Urine Void Collection Containers ..................................................................................  58 9.11
10.0 VISIT 5 (WEEK 6 / DAY 42 ± 3) ........................................................................................................ 58 
 Review of Inclusion / Exclusion Criteria ................................................................................................  58 10.1
 Vital Signs ..............................................................................................................................................  59 10.2
 Review of Concomitant Medications ..................................................................................................... 59  10.3
 Review of Tobacco and Nicotine Restrictions .......................................................................................  59 10.4
 Review of Adverse Events .....................................................................................................................  59 10.5
 Confirm Regular Cigarette Brand / Photocopy Cigarette Pack ..............................................................  [ADDRESS_591347] Dispensation ........................................................................................................ 60 10.10
 Exhaled CO Measurement ......................................................................................................................  61 10.11
 SMS System Use .................................................................................................................................... 61 10.12
 BOE and BOPH Urine Sample Collection .............................................................................................  61 10.13
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 7 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   BOPH and COHb Blood Sample Collection ..........................................................................................  61 10.14
11.0 VISIT 6 (WEEK 9 / DAY 63 ± 3) ........................................................................................................ 61 
 Review of Inclusion / Exclusion Criteria ................................................................................................  62 11.1
 Vital Signs ..............................................................................................................................................  62 11.2
 Review of Concomitant Medications ..................................................................................................... 62 11.3
 Review of Tobacco and Nicotine Restrictions .......................................................................................  62 11.4
 Review of Adverse Events .....................................................................................................................  62 11.5
 Confirm Regular Cigarette Brand / Photocopy Cigarette Pack ..............................................................  [ADDRESS_591348] Urine Void Collection Containers ..................................................................................  64 11.11
12.0 VISIT 7, END OF STUDY (WEEK 12 / DAY 84 ± 3) ....................................................................... 64 
 Review of Inclusion / Exclusion Criteria ................................................................................................  64 12.1
 Vital Signs ..............................................................................................................................................  65 12.2
 Body Weight and Body Mass Index ....................................................................................................... 65 12.3
 Spi[INVESTIGATOR_038] ..............................................................................................................................................  65 12.4
 Physical Examination (Symptom Driven) ..............................................................................................  [ADDRESS_591349] .............................................................................................................................  67 12.8
 Review of Concomitant Medications ..................................................................................................... 67 12.9
 12-Lead ECG .......................................................................................................................................... 67 12.10
 Review of Adverse Events .....................................................................................................................  67 12.11
 Confirm Cigarette Brand / Photocopy Cigarette Pack ............................................................................  [ADDRESS_591350] Collection ............................................................................................................  67 12.15
 Exhaled CO Measurement ......................................................................................................................  68 12.16
 SMS System Use .................................................................................................................................... 68 12.17
 BOE and BOPH Urine Sample Collection .............................................................................................  68 12.18
 BOPH and COHb Blood Sample Collection ..........................................................................................  68 12.19
 Reasons of Use/Not-Use Test Product Questionnaire (Test group only) ...............................................  68 12.20
 mCEQ Questionnaire ..............................................................................................................................  68 12.21
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 8 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   End of Study Questionnaire ....................................................................................................................  69 12.22
13.0 ADVERSE EVENTS ............................................................................................................................  69 
 Serious Adverse Events ..........................................................................................................................  71 13.1
 Adverse Events / Serious Adverse Events Follow Up ............................................................................  [ADDRESS_591351] DISCONTINUATION ....................................................................................................... 74 
17.0 CLINICAL LABORATORY SAMPLES ...........................................................................................  76 
18.0 BIOANALYTICAL LABORATORY ................................................................................................  76 
 BOEs Urine (1st void of the day): ........................................................................................................... 78 18.1
 BOE Blood (after overnight fasting, at least 8 hrs): ...............................................................................  78 18.2
 BOPHs Urine (1st void of the day): ........................................................................................................ 78 18.3
 BOPHs Blood (after overnight fasting, at least 8 hrs): ........................................................................... 78 18.4
 Urine Creatinine (1st void of the day) ..................................................................................................... 78 18.5
19.0 STATISTICAL METHODS ................................................................................................................  79 
 Statistical Analysis Plan .........................................................................................................................  79 19.1
 Sample Size Estimation ..........................................................................................................................  79 19.2
 Randomization ........................................................................................................................................ 80 19.3
 Criteria for Evaluation ............................................................................................................................  80 19.4
19.4.1  Primary Endpoints .................................................................................................................  80 
19.4.2 Secondary Endpoints .............................................................................................................  81 
19.4.3  Exploratory Endpoints ........................................................................................................... 81 
19.4.4  Clinical Safety Endpoints ...................................................................................................... 81 
 Analyses Data Set ................................................................................................................................... 82 19.5
19.5.1  Demographics and Baseline Characteristics .......................................................................... 83 
19.5.2  Endpoint Analyses .................................................................................................................  83 
 Dealing with Missing Data .....................................................................................................................  84 19.6
 Subgroup Analysis ................................................................................................................................ . 85 19.7
20.0 DATA MANAGEMENT ......................................................................................................................  85 
 Database Design and Creation ................................................................................................................  85 20.1
 Data Coding ............................................................................................................................................  85 20.2
 Data Entry and Verification ....................................................................................................................  85 20.3
 Study Results Data Transfer ...................................................................................................................  86 20.4
 Data Validation ....................................................................................................................................... 86 20.5
 Database Lock ........................................................................................................................................ 86 20.6
21.0 MONITORING THE STUDY .............................................................................................................  86 
22.0 REPORTING FOR THE STUDY ....................................................................................................... 87 
 Case Report Forms ................................................................................................................................ . 87 22.1
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 9 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591352] .....................................................................................................................  88 23.4
 Termination of Study ..............................................................................................................................  89 23.5
 Study Records Retention ........................................................................................................................  89 23.6
24.0 REFERENCES ..................................................................................................................................... 90 
APPENDECES 
 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 10 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  STUDY SYNOPSIS 
ALCS Protocol Number:   
ALCS -RA-16-06-EV 
Abbreviated Protocol Title:   
e-Vapor  SWITCH ing Study to Assess  Health Risk s in Adult Smokers (e-SWITCH ) 
Long Protocol Title:   
An Open -Label, Randomized, Parallel -Group, Controlled Study to Evaluate Changes in 
Biomarkers of Cigarette Smoke Exposure and Biomarkers of Potential Harm in Adult 
Smokers Who Completely Switch to Using e-Vapor  Products for [ADDRESS_591353] s: 
Test e-Vapor  products  (supplied by [CONTACT_461953] ): 
• Product XLCB = Test EVP (currently marketed by [CONTACT_41677]® 
XL Bold Classic [4.0% NBW]) [CVR2.6.8] Formula: [ZIP_CODE] -44-B; Name: 
“Rosetta”; Label: B44  
• Product XLMB = Test EVP (currently  marketed by [CONTACT_41677]® 
XL Bold Menthol [4.0% NBW]) [CVR2.6.8] Formula: [ZIP_CODE] -40-E; Name: 
“Spencer”; Label: 40E   
Reference product  (supplied by [CONTACT_461954]) : 
• Subject’s own brand1 commercially available conventional cigarettes  
1 own brand: subject’s choice, no restriction on brand at any time during the study  
Number of Subjects and Groups : 
Total number of adult subjects (to randomize): 450  will be randomized in total, with 
150 subjects into each of the groups described below  to better ensure that a minimum 
of 120 in each group  complete the study . 
Three study groups:  
• Test 1 Group (n=150): Exclusive ad libitum use of test e-Vapor  Product XLCB , 
without use of any other type of tobacco/nicotine containing product, for the 
entire 1 2 weeks  
• Test 2 Group (n=150): Exclusive  ad libitum use of test e-Vapor  Product XLMB , 
without use of any other type of tobacco/nicotine containing product, for the 
entire 12  weeks  
• Control Group (n=150):  Continue smoking under ad libitum use of subjects’ own 
brand of conventional lit -end cigarettes, without use of any other type of 
tobacco/nicotine containing product, for the entire 12  weeks  
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 11 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  Study Duration:  
16 weeks  (up to 4 week s for screen ing + 12 week s from randomization to the End of 
Study [ EOS ]) 
Estimated Study site s:  
6-10 study site s 
Study Objectives:  
The Primary Objective is to:  
Compare absolute changes in selected biomarkersa from Baseline  to End of Study (EOS) 
between adult smokers who continue to smoke conventional cigarettes ( Control group ) 
ad libitum and adult smokers who have completelyb switched to ad libitum use of the test 
e-Vapor  products ( Test group s) for 12 weeks .  
a Seleted biomarkers include:  
o White Blood Cell Count ( WBC ) 
o High Density Lipoprotein Cholesterol ( HDL -C)  
o Urinary 8-epi-prostaglandin F 2α 
o Urinary 11 Dehydrothromboxane B 2 
o Blood Soluble Intercellular Adhesion Molecule -1 (sICAM -1)  
o Urinary 4 -(methylnitrosamino) -1-(3-pyridyl) -1-butanol and its 
glucuronides ( total NNAL )  
o Carboxyhemoglobin ( COHb )  
b Subjects who exclusively use e-Vapor  product s and with eCO measurements < 8 ppm 
from Week 3 through EOS  
The Secondary Objectives are to:  
 Compare changes in selected biomarkers (same as those in the primary objective) 
from Baseline  to Week  [ADDRESS_591354] and Control  groups  
 Determine the number  of cigarette s smoked (Test and Control groups ) from Week 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 12 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  2 through EOS  
 Assess changes in the amount of  test e-Vapor  product use (Test groups only) from 
Week 2  through EOS   
 Assess adherence to protocol by [CONTACT_461955]:  
 Assess changes in BOPHs and  BOEs (same as in the primary objective) from 
Baseline to Week 6 and EOS in two subgroups that use different flavored e-Vapor  
products  
 Assess changes in forced expi[INVESTIGATOR_104763] ( FEV 1), forced 
vital capacity ( FVC ) and FEV 1/FVC  ratios f rom Screening/Visit [ADDRESS_591355] and Control  groups  
 Assess changes in urine nicotine equivalents ( NE) from Baseline  to Week  [ADDRESS_591356] and Control  groups  
 Assess  changes in  the QGEN and TQOLIT questionnaires  and the Cough 
Questionnaire responses from Baseline  to EOS  between the Test and Control  
groups  
 Assess reasons for  test product  use/not -use at EOS and mCEQ questionnaires 
from Baseline to  EOS  for the Test group s 
 Collect  blood and urine samples for future assessment of BOE and or BOPH  
Study Design:   
 
This research study will utilize a randomized, parallel -group, open -label, controlled 
design and will be conducted at multiple  study site s. Up to 450 adult male and female 
(neither  gender sh ould account for more than 60% of the population) smokers ( 30 to 65 
years of age, inclusive) with ≥ 10 years of smoking and an average  daily cigarette 
consumption of ≥ 10 CPD  in the 12 months prior to Screen ing, Visit 1, will be 
randomized into one of the three study groups at Visit  3. Subjects that pass the initial 
screening at Visit 1 (Screen Part 1) will be asked to return to the study site  for a test 
product trial at Visit 2 (Screen Part 2).  During the test product trial, potential subjects 
will be allowed to  use each of the Test Products for 15 minutes with 30 minutes in 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 13 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591357] products will be randomized at Visit 3 (Day 1) to 
one of the study groups . 
All sub jects will report their cigarettes per day (CPD) (Control and Test groups) and Test 
product use (Test groups only) daily using a Short Message Service  (SMS), i.e., text 
message, based system (Med -Quest) . The self-reported CPD , use of other tobacco 
products,  and measurements  of CO and NNN  taken during  the in -clinic visits after 
randomization will be used to monitor subject compliance  with exclusive use o f the test 
products . All subjects will return to the study site s for four visits at Week s 3, 6, 9 and 12. 
Study Diagram:   
 
 
Study Visits:  
 
 Visit 1: Screening Part 1 (Day -28 to Day -7) 
 Visit 2: Screening Part 2 (Visit 1 to Day -5)  
 Visit 3: Randomization  (Week 1, Day 1) 
 Visit 4: (Week 3, Day 21 +/ - 3 days) 
 Visit 5 : (Week 6, Day 42 +/- 3 days) 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 14 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Visit 6: (Week 9, Day 63 +/ - 3 days) 
 Visit 7: (Week 12, Day 84 +/- 3 days, EOS [or Early Term ination] )  
 
Number of Subjects per Group:   
Up to 450 healthy adult cigarette smokers will be randomized (stratified by [CONTACT_262962] , gender,  and age) in a 1:1:[ADDRESS_591358] 2 and Control groups to ensure that 
120 from each group will complete the study. Neither gender should account for  more 
than 60% of the s tudy population.  
Randomization Schema  
 
 Control group: n = 150 (own brand conventional cigarettes)  
 Test 1 group: n = 150 (Product XLCB ) 
 Test 2 group: n = 150 (Product XLMB ) 
Study Population:   
The study population will consist of up to 450 adult ( 30 – 65 years of age) cigarette 
smokers who satisfy all inclusion/exclusion criteria.  
 
Inclusion criteria:  
Subjects must satisfy the following criteria before being enrolled into the study.  Subject s 
must:  
1) sign an IRB -approved informed consent form (ICF) for the study;  
2) be between the ages of 30 and 65 years, inclusive, at the time of 
Screening, Visit 1;  
3) have > 500 ng/ml urine cotinine measurement at Screening , Visit 1;  
4) have smoked for ≥ 10 years and smoked an average of ≥ 10 manufactured 
cigarettes per day during the  12 months  prior to Screening , Visit 1 ; 
a) Brief periods [i.e., up to 7  consecutive days] of non -smoking during 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 15 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  the 12  months prior to Screening, Visit  1 due to illness, trying to 
quit, or participation in a study where smoking was prohibited are 
acceptable . 
5) indicate that he/she is “definitely”  or “probably”  willing and able to 
replace their cigarettes for [ADDRESS_591359];  
6) have daily access to text messaging capable cellular phone for daily 
product use reporting ;  
7) have  a negative ethanol  breath test  and amphetamines, opi[INVESTIGATOR_858], 
cannabinoids, and cocaine urine drug screen results  at Screening, Visit 1 ; 
a) Subjects with a prescription from a licensed physician will not be 
exempted from this criterion.  
8) if female  (all females) , have a negative serum pregnancy test at Visit [ADDRESS_591360] at Visit 2  through Visit 7, inclusive ; 
9) if female, heterosexually active, and of childbearing potential (i.e., not 
surgically sterile or 2 years naturally postmenopausal), must have used a 
medically accepted method of contraception (listed below in a) and b)) 
prior to Screening , Visit [ADDRESS_591361] agree to  continue to  use such 
method(s) through the End  of Study ; 
a) Surgically sterile includes bilateral tubal ligation, Essure, 
hysterectomy, or bilateral oophorectomy at least 6 months prior to 
Screening , Visit 1 . Naturally postmenopausal is defined as women 
having 2  years without menses.  
b) Acceptable methods of contracep tion are:  hormonal (i.e., oral, 
transdermal patch, implant, or injection) consistently for at least 
3 months prior to Screening , Visit 1 ; double barrier (i.e., condom 
with spermicide or diaphragm with spermicide) consistently for at 
least 4 weeks prior to Screening , Visit 1 ; and intrauterine device for 
at least 3  months prior to Screening , Visit 1 ; or only have a partner 
who has been vasectomized for at least 6  months prior to Screening , 
Visit 1 . 
10) Be willing and able to comply with the requirements of the study.  
   
Exclusion criteria:  
Subjects may be excluded from the study if there is evidence of any of the following 
criteria.  Exceptions may be permitted at the discretion of the Investigator and in 
consultation with the Sponsor or designee provid ed there would be no additional risk to 
the subject.  Any exceptions will be documented.   
1) History or presence of clinically significant gastrointestinal, renal, hepatic, 
neurologic, hematologic, endocrine, onc ologic, urologic, diabetes, existing 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 16 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591362] the validity of the study 
results.  (Note: chronic medical conditions controlled and on stable 
medications  [over past 3 months]  may not necessarily be exclusionary per 
Investigator discretion) ;  
2) Currently taking medication for depression, asthma or diabetes;  
3) Allergy to menthol ; 
4) Systolic blood pressure > 1 40 mmHg and / or diastolic blood pressure > 
90 mmHg at Screen ing Visit 1.  
5) Have clinically significant abnormal findings on the physical examination, 
vital signs , electrocardiogram ( ECG ), or medical history that would 
jeopardize the safety of the subject , in the opi[INVESTIGATOR_689] ;  
6) Positive test for human immunodeficiency virus ( HIV), hepatitis B surface 
antigen ( HbsAg ), or hepatitis C virus ( HCV ) at Screening, Visit 1 ; 
7) Current evidence or any history o f congestive heart failure ; 
8) Any acute illness (e.g., upper respi[INVESTIGATOR_4416], viral infection) 
requiring treatment within 2  weeks before Visit 3 (Day 1); 
9) History of drug or alcohol abuse within 24 months of Visit 3 (Day  1) as 
defined by [CONTACT_12244] r; 
10) BMI greater than 40 .0 kg/m2 or less than 18 .0 kg/m2 at Screening, Visit 1 ;  
11) Post-bronchodilator FEV 1:FVC ratio < 0.7 and FEV 1 < 50% of predicted  
at Screening, Visit 2 ; 
12) Post-bronchodilator FEV1:FVC ratio < 0.75 and FEV1 increase ≥ 12% 
and > [ADDRESS_591363] -bronchodilator at Screening, Visit 2;  
13) Estimated creatinine clearance (by [CONTACT_3158] -Gault equation) < 80 
mL/min at Screening, Visit 1 ; 
14) Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase 
(AST) > 1.5 times the upper limit of the reference range at Screening, 
Visit  1; 
15) Female candidates who are pregnant, lactating, or intend to become 
pregnant from Screening , Visit 1  through End of Study; 
16) Use of HDL -C raising medication / supplements (e.g., niacin, 
gemfibrizole, fenofibrate, etc.)  within the past 3 months prior to 
Screening, Visit 1 or any time during the study;  
17) Use of nicotine -containing products other than manufactured cigarettes 
(e.g., roll -your-own cigarettes, e -cigarette or e-Vapor  products, Bidis, 
snuff, nic otine inhaler, pi[INVESTIGATOR_5836], cigar, smokeless tobacco, nicotine patch, 
nicotine spray, nicotine lozenge, or nicotine gum) within 14 days prior to 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 17 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  Screening, Visit 1  through Visit 3 (Day 1) except as required for the 
purpose of this study ; 
18) Donation of blood or bloo d products , including plasma,  history of 
significant blood loss  in the opi[INVESTIGATOR_871] , or receipt of 
whole blood or a blood product transfusion within 60 days prior to Visit 3 
(Day 1); 
19) Participation in a clinical study of an investigational drug, medical device, 
biologic , or of a tobacco product, within 30 days before Visit 3 (Day 1); 
20) Participation in more than two ALCS studies within 12 months before 
Visit 3 (Day 1); 
21) Already enrolled or failed screening for the current study at a different  
study site ;  
22) Subject or a first -degree relative (i.e., parent, spouse, sibling, or child ) is a 
current or former employee of the tobacco industry or a named party or 
class repre sentative in litigation with any tobacco company . 
Study Duration:   
The expected duration of the study, from first subject, first visit through last subject, 
last visit will be approximately [ADDRESS_591364] is approximately 1 6 weeks.   
Statistics:   
Sample size estimation  
 
The study is designed  to detect a statistically significant difference in change from 
baseline to the end of the study in [ADDRESS_591365] and 
the Control g roups. Total NNAL, COHb, 11 -Dehydrothromboxane B 2, 8-epi-
prostaglandin F 2α WBC and HDL values from a previous PM[LOCATION_003] longitudinal study 
(Study #: EHCJLI/02/02) for the Electronic Heating Cigarette Smoking System and S -
ICAM values from another source  (Scott D A et. al. 2000 ) were used for the sample size 
calculation . Assuming a two -sided test, 3.5 % Type I error rate (adjusted for multiplicity 
of detecting statistical significance in 5 out of the 7 biomarkers  based on the Hailperion -
Ruger  approach ), 80% power and a [ADDRESS_591366] group and 120 in the Control group are needed. 
With a 15% dropout rate expected, [ADDRESS_591367] groups and one control group, a total of 450 subjects ([ADDRESS_591368] and 150 
in Control groups) are needed at the randomization . The statistical power for each 
primary biomarker is provided below.  
 
Table 1.  Approximate power for a preliminary sample size of test=120  and 
control=120 subjects  
 
Biomarker  Cigarette Smoker 
(mean, SD)  Electrically Heated Cigarette 
Smoker or Quitter (mean, SD)  Power (%)  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 18 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  Total NNAL (ng/g Cr)1 484.51 (187.50)  86.90 (134.19)  >85 
COHb (AUC (7-23h), % •hr)2 3.6 (18.1)  -70.7 (35.4)  >85 
8-Epi (ng/g Cr )3
 1320 (506.78)  1106.28 (456.74)  85 
11-Dehydro (mg/g Cr)1 1264.00 (533.58)  1011.53 (385.33)  >85 
WBC (X1,000/ul)2 -0.3 (1.3)  -1.1 (1.3)  >85 
HDL (mg/dl)2 0 (7.0)  5.0 (10.0)  >85 
sICAM -1 (ng/ml)4 5 (66.0)  -66.1 (75.0)  >85 
 
All biomarker data except S -ICAM are from the PM[LOCATION_003] EHCSS JLI long term study21.  
1. Week 13 value  
2. Change from baseline to Week 13  
3. Average value of Week 8 and Week 17 due to potential bioanalytical data issue for Week 13  
4. Scott D et. al. (2000 )22.  
 
Hypothesis  
 
If adult cigarette smokers completely switch  to the test e-Vapor  products for [ADDRESS_591369] 5 out of 7 
biomarkers demonstrating a statistically significant change  from baseline  compared to 
cigarette smoking.   
Primary Endpoints  
 
The primary endpoint s are change s from baseline to the end of study in the following 
biomarkers measured at Baseline (Day 1) and End of Study ( Week 12 ): 
 
1) WBC in whole blood (103 µg/L) 
2) HDL -C in serum  (mg/dL)  
3) 8-epi-prostaglandin F 2α in urine  with creatinine adjusted  (ng/g Cr) 
4) 11-dehydrothromboxane B 2 in urin e with creatinine adjusted (ng/g Cr) 
5) Soluble Intercellular Adhesion Molecule – 1 (sICAM -1) in serum (ng/mL)  
6) Total NNAL in urine with  creatinine adjusted (ng/g Cr)  
7) COHb in whole blood (% sat)  
Secondary Endpoints  
The secondary endpoints are:  
1) Levels of selected biomarkers  (same as the primary endpoints) and the 
following additional biomarkers  measured at Baseline/Day 1 (Visit 3), 
Week 6 (Visit 5) and EOS (Visit 7): 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 19 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  a) Creatinine -adjusted NNN in urine  (ng/g Cr) and exhaled CO.  
2) The average daily cigarette s smoked  and Test Product use re ported by 
[CONTACT_1130] s during  Week 2 through Week 6 and during Week 7  through EOS    
a) Test Product The Test Products used per day, the number of  new 
cartridges  used, and average number of puffs taken (1 – 20 or >20) 
will be document through text message.  
b) The number of cigarettes smoker per day will be documented by [CONTACT_461956] t he text message.  
 
Exploratory Endpoints  
The exploratory endpoints are:  
1) Assess changes in BOPHs and  BOEs (same as in the primary objective) 
from Baseline to Week [ADDRESS_591370]  
e-Vapor  Products  
2) FEV1 (% predicted),  FCV, and FEV1/FVC measured at Screening (Visit 
2) and EOS  
3) Nicotine Equiv alents (Nicotine, Cotinine, Trans -3'-Hydroxycotinine, 
Trans -3'- Hydroxycotinine -O-glucuronide, Nicotine -N-glucuronide, and 
Cotinine -N-glucuronide) ( NE) in urine with creatinine adjustm ent (mg/g 
Cr) measured at Baseline/Day 1 (Visit 3), Week 6  (Visit 5) and EOS  
4) Responses (Score) to the QGEN and TQOLIT  questionnaires  and the 
Cough Questionnaire recorded at Baseline/Day 1 (Visit 3), Week 6  (Visit 
5) and EOS  
5) Reponses to Reasons for Use and Not -use of Test Product  (EOS)  and 
mCEQ questionnaire s (Baseline/Day 1 [Visit 3])  (Test group only)  
Statistical Analysis Methods  
Demographic Variables  
Demographic baseline characteristics will be summarized by [CONTACT_461957] (the number of non -missing values, mean, median, standard 
deviation [SD], minimum, maximum, coefficient of variation [ CV], 95% confidence 
interval) for continuous variabl es (e.g., BMI) and frequency counts for categorical 
variables (e.g., gender).   
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 20 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  Primary and secondary variables   
Primary variable analysis  
A linear mixed model for repeated measures (MMRM) analysis will be used for 
comparing each Test group to the Control g roup in the mean absolute change from 
Baseline to EOS  in each primary endpoint . In the model, study group, visit , and study 
group by [CONTACT_23259], gender, age class, race and BMI class are the fixed effect 
factors.  The baseline value of the response b iomarker is the fixed effect covariate and 
subject is the random effect factor. The unstructured covariance structure will be used 
for modeling covariance. The least -square mean difference, 95% confidence interval 
and p -value will be provided for the group  difference. The analysis will be conducted 
on the MITT population.  
 
To assess the robustness of the primary MMRM analysis to the possible  violation of 
the missi ng at random (MAR) assumption, t he pattern mixture  model based on the non -
future dependent miss ing value restriction will be applied . In addition, a supportive 
analysis based on the per -protocol (PP) population will also be conducted.  
 
Secondary variable analyses   
 
1) The MMRM as used for the primary endpoints will be used to test the differences 
in the mean absolute change from Baseline to Week 6 for the selected biomarkers 
(WBCs, HDL -C, COHb, total NNAL, 8 -epi-prostaglandin F 2α, 11-
Dehydrothromboxane B 2, and sICAM -1) between each Test group and the 
Control group. 
  
2) Descriptive statistics ( the number of subjects with non -missing data, number of 
subjects with missing data, mean, standard deviation, median, minimum and 
maximum ) will be used to summarize the average cigarette s per day and daily e-
Vapor  cartridge consumption amount  by [CONTACT_461958] 2 through Week 6 and 
from Week 7 through EOS . Frequency tables will also be used to summarize the 
proportions of change categories (reduce, no change, increase or percentage) from 
baseline to end of st udy for each study group .  
 
3) A frequency table (n and %) will be used to summarize  use of other tobacco 
products, eCO and NNN for assessment of  compliance and noncompliance for 
each study group . 
 
Exploratory Endpoints/Variable Analyses  
 
The MMRM approach will be used to provide the estimates for:  
 changes in BOPHs and  BOEs  from Baseline  to Week 6  and EOS  in two 
subgroups that use different flavored e-Vapor  products  
 changes in forced expi[INVESTIGATOR_104763] ( FEV 1), forced vital 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 21 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  capacity ( FVC ), and FEV 1/FVC  ratios from Baseline  to EOS  in the Test and 
Control groups  
 changes in urine nicotine equivalents ( NE) from Baseline  to Week [ADDRESS_591371] and Control  groups  
 changes in the QGEN and TQOLIT  questionnaires  and the Cough Questionnaire 
from Baseline  to EOS  in the Test and Control  groups  
 
Subgroup Analysis  
Subgroup analyses will be conducted for the end of study change from baseline in the 
primary biomarkers by [CONTACT_461959], product and age class and product and BMI 
class using the MMRM model.  
Clinical Safety  
Adverse Event s (AE) will be coded with the Medical Dictionary for Regulatory 
Activities (MedDRA®). 
AEs will be listed in by -subject data listings.  Frequency counts of AEs will be provided 
by [CONTACT_461960] m organ class and preferred terms, and study group. Frequency counts of AEs 
will also be listed and summarized by [CONTACT_461961].  
Clinical safety analyses will include summaries of clinical safety measures (blood 
pressure, ECG, vital  signs, clinical chemistry, and hematology ). 
 
More details about the data analysis will be described in the Statistical Analysis Plan 
(SAP) . 
 
All statistical analyses will be performed with SAS® software.   
 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 22 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  SUMMARY OF EVENTS/ASSESSMENTS 
EVENTS/ASSESSMENTS  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  
Screening 
Part 1  
(Day -28 
through 
Day -7) Screening 
Part 2  
(After the 
results of 
Part 1 are 
assessed 
through Day 
-5) Week 1  
Day 1  Week 3  
Day 21 
(+/- 3) 
 Week 6  
Day 42 
(+/- 3) 
 Week 9  
Day 63 
(+/- 3) 
 Week 12  
Day 84 (+/ - 3) 
End of Study / 
Early Term  
Age Verification and Photocopy of ID  X       
Informed Consent  X       
Urine Drug Screen and Alcohol  Breath 
Test X       
Medical History  X       
Demographics and Tobacco Use History 
Questionnaires  X       
Photocopy Cigarette Pack1 X       
Review of Inclusion / Exclusion Criteria  X X X X X X X 
Vital Signs2 X X X X X X X 
Body Weight  X  X    X 
Height  X       
Body Mass Index  X  X    X 
Spi[INVESTIGATOR_038]3  X     X 
Smoking Cessation  Information  X      X 
Clinical Chemistry ( 8 hr fasting)  X      X 
Hematology (8  hr fasting)  X      X 
Urinalysis  X      X 
HIV, HbsAg, and HCV Serology  X       
Urine Cotinine Screen  X       
Serum Pregnancy Test (females)  X       
Review of Concomitant Medications  X X X X X X X 
Review of Tobacco and Nicotine 
Restrictions  X X X X X X  
Physical Examination   X X4    X4 
12-Lead ECG5  X     X 
Urine Pregnancy Test   X X X X X X 
Test e-Vapor  product trial   X      
Test e-Vapor  Product(s) Assessment  
Questionnaire   X      
Review of AEs   X X X X X X 
QGEN and TQOLIT  questionnaires    X  X  X 
Cough Questionnaire    X  X  X 
mCEQ  Questionnaire    X    X 
Reasons of Use/Not -Use Test Product       X 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 23 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  EVENTS/ASSESSMENTS  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  
Screening 
Part 1  
(Day -28 
through 
Day -7) Screening 
Part 2  
(After the 
results of 
Part 1 are 
assessed 
through Day 
-5) Week 1  
Day 1  Week 3  
Day 21 
(+/- 3) 
 Week 6  
Day 42 
(+/- 3) 
 Week 9  
Day 63 
(+/- 3) 
 Week 12  
Day 84 (+/ - 3) 
End of Study / 
Early Term  
Questionnaire10 
Confirm Regular Cigarette Brand   X X11 X11 X11 X11 X11 
Subject Randomization    X     
Test e-Vapor  Product Dispensation    X X X X  
Test e-Vapor  Product Collection     X X X X 
Subject Instructions for Product Use   X      
Reminder Phone Calls    X X X X X 
Distribute 1st Morning Void Containers   X  X  X  
Urine (1st void of day) for BOEs and 
BOPHs6, 7   X  X  X 
Blood Collection for BOPHs8   X  X  X 
Blood Collection for COHb8   X  X  X 
BioBanking    X  X  X 
–Product Use Reporting  Training    X     
Product Use Reporting9   X X X X X 
Exhaled CO Measurement    X X X X X 
End of Study Questionnaire        X 
AE = adverse event; BOE = biomarker of exposure; BOPH = biomarker of potential harm; CO = carbon monoxide; 
COHb = carboxyhemoglobin; CPD = cigarettes per day; ECG = electrocardiogram; FEV 1 = forced expi[INVESTIGATOR_3741] 1 second ; 
FVC = forced vital capacity ; HbsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HDL-C = high-density lipoprotein 
cholesterol; HIV = human immunodeficiency virus; ID = identification; IV RS = interactive voice response system; NE = nicotine 
equivalents; NNAL = 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol; sICAM-1 = Soluble intercellular adhesion molecule-1 ; 
WBC = white blood cell. 
  
[ADDRESS_591372]’s regular cigarette has changed. 
2 Vital signs (respi[INVESTIGATOR_697], pulse rate, blood pressure, and oral temperature) in the sitting position after at least [ADDRESS_591373] used. 
3 Spi[INVESTIGATOR_461918] 1, FVC, and FEV 1/FVC ratio measurements. 
4 Brief physical examination (symptom driven). 
[ADDRESS_591374] 5 minutes resting in supi[INVESTIGATOR_2547]. 
6 Urinary creatinine will be measured in all urine samples to allow for adjustment of all urine biomarkers. 
7 Spot urine (first void of the day, after at least 4 hrs since prior void) collections will be used for the analysis of BOEs (total 
NNAL, NE, NNN) and BOPHs (11-Dehydrothromboxane B 2, 8-epi-prostaglandin F 2α).  
8 Blood will be collected after overnight fasting (at least 8 hrs) and will be used for the analysis of COHb and BOPHs (WBC, 
sICAM-1, HDL- C). 
[ADDRESS_591375] use (conventional cigarettes or test e-Vapor product) will be reported daily (Day 1 through Day 84/Week 12) 
by [CONTACT_25439] a Short Message Service (SMS), i.e., text message, based system (Med-Quest) to assess product use and 
compliance during the study. 
[ADDRESS_591376] group only. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 24 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  11  Control group only, photocopy the pack if there has been a change from Screening. 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 25 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591377]  Aspartate aminotransferase  
BMI  Body mass index  
BOE  Biomarker of exposure  
BOPH  Biomarker of potential harm  
BUN  Blood urea nitrogen  
°C Degrees Celsius  
CDMS  Clinical Data Management System  
CFR  Code of Federal Regulations  
CLIA -88 Clinical Laboratory Improvement Amendments of 1988  
CO Carbon monoxide  
COHb  Carboxyhemoglobin  
CPD  Cigarettes per day  
CRF  Case report form  
CRO  Clinical Research Organization  
CSP Clinical safety population  
CV Coefficient of variation  
DMP  Data management plan  
ECG  Electrocardiogram  
°F Degrees Fahrenheit  
FVC  Forced vital capacity  
FDA  Food and Drug Administration  
FEV1  Forced expi[INVESTIGATOR_3741] [ADDRESS_591378]  
ITT Intent to treat  
IVRS  Interactive Voice Response System  
Kg Kilogram(s)  
LED  Light -emitting diode  
M Meter(s)  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram(s)  
MITT  Modified intent to treat  
mL Milliliter(s)  
MMRM  Mixed model for repeated measures  
N Number, sample size  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 26 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  NBW  Nicotine by [CONTACT_461962]  4-(methylnitro samino) -1-(3-pyridyl) -1-butanol  
pg Pi[INVESTIGATOR_461919]-protocol  
QA Quality assurance  
RBC  Red blood cell  
SAE  Serious adverse event  
SAP Statistical analysis plan  
sICAM -[ADDRESS_591379] deviation  
SOP(s)  Standard operating procedure(s)  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopoeia  
WBC  White blood cell  
WHO -DD World Health Organization Drug Dictionary  
 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 27 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  1.0 INTRODUCTION AND STUDY RATIONALE 
 Background 1.1
Innovative and novel tobacco derived nicotine products, like e-Vapor products (EVPs) 
potentially offer reduced risk alternatives to adult consumers of conventional lit-end cigarettes 
(CCs)1. The proven strategies of prevention and cessation can be complemented by [CONTACT_461963].  There is overwhelming 
scientific evidence regarding a risk continuum in the range of tobacco products available 
currently in the market. According to this body of evidence, combustible tobacco products, like 
CCs, are the most risky and non-combustible tobacco products, like EVPs present relatively 
lower risks. The Royal College of Physicians' new report, ‘Nicotine without smoke: tobacco 
harm reduction’2, has concluded that EVPs are significantly less risky than cigarettes and likely 
to be benefit public health. EVPs deliver nicotine in an aerosol that has a very different 
composition than a typi[INVESTIGATOR_461920]. There are thousands of chemicals generated from 
the combustion of tobacco, many of which are carcinogenic3, 4.  In contrast, far fewer chemicals 
are generated from heating an e-liquid consisting of carrier ingredients (usually propylene glycol 
[PG] and/or glycerol), nicotine, water and flavors5. The likely reductions in exposure due to large 
differences in the chemical composition of aerosols between the cigarettes and EVPs presents 
harm reduction opportunities for adult smokers switching to EVPs.  Nu Mark LLC (Nu Mark) is 
focused on responsibly developi[INVESTIGATOR_41652], such as e-Vapor 
products, that may reduce the risk of tobacco-related disease.  Altria Client Services LLC 
(ALCS) and Nu Mark are undertaking various studies to evaluate the EVPs including the 
MarkTen® branded e-Vapor products. These studies will provide the scientific evidence in 
support of a Premarket Tobacco Product Application (PMTA) submission to the Center of 
Tobacco Products at FDA. Before issuing a marketing order, FDA must determine, based on the 
contents of the PMTA and other data available to FDA, that marketing the new product that is 
the subject of the PMTA would be appropriate for the protection of the public health.  FDA’s 
Draft PMTA Guidance for Electronic Nicotine Delivery Systems6 (ENDS or in other words 
EVPs) (Draft ENDS PMTA Guidance) suggests that applicants include,in addition to other 
information, results from studies addressing topography and use patterns, an assessment of abuse 
liability and results from human studies assessing biomarkers and health risks.  This study will 
assess biomarkers and health risks  in adult smokers who switch to EVP products or continue 
smoking cigarettes.  This study is one component of a broader comprehensive framework that 
will provide the totality of evidence for the PMTA.  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 28 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  In the following sections we briefly describe the preclinical studies on the products proposed for 
testing in this study as well as human studies conducted on earlier versions of MarkTen® 
branded products.  
 Product Safety Information 1.[ADDRESS_591380] toxicological assessment (“Product Stewardship [PS]”) 
program based on the concept that, while the use of any tobacco product has an inherent risk, 
ingredients and components used in Nu Mark’s  products and any interaction of e-Vapor device 
and e-liquid to form aerosols should not increase the inherent risk.  The toxicological assessment 
is based on the totality of all of the available scientific evidence and, when appropriate, considers 
the harm reduction potential of EVPs for cigarette smokers.  
Nu Mark uses the highest quality ingredients available, including, food-grade GRAS flavors and 
USP-grade aerosol formers (propylene glycol and glycerol) and nicotine. The use levels are 
determined based on estimated consumer usages, material-specific scientific data in the 
literature, and applicable regulatory information.  
Tox
icological data are already available for many individual ingredients commonly used in 
consumer products. However, there is no toxicological data on specific product formulations.  
Therefore ALCS uses a weight-of-evidence approach in assessing e-Vapor ingredients and 
products considering the following information: 
• Individual material evaluation & risk assessment 
• Chemistry analyses of formulations and product aerosols 
• Flavor mixtures (prototype formulations): in vivo inhalation study in rats 
• Product-specific formulation: in vitro (genotoxicity and cytotoxity) testing   
The approach is consistent with FDA’s recommendations in the Draft ENDS PMTA Guidance 
(May 2016)7, for “a full assessment of the toxicological profile associated with the new product, 
which includes in vitro and in vivo toxicological studies”6. In the assessment of genotoxicity 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 29 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  potential, FDA refers to International Conference on Harmonization (ICH) S2(R1)7 guidance and 
Organization for Economic Cooperation and Development (OECD) protocols8-12.   
ALCS has performed the following battery of in vitro tests and if needed, in vivo genotoxicity 
test for the relevant e-liquid formulations: 
1. In vitro bacterial gene mutation test (Ames assay; OECD471)[ADDRESS_591381] (Neutral Red Uptake [NRU] assay; OECD129)[ADDRESS_591382] (micronucleus [MN] assay; OECD487)8, a nd 
4. (if needed) In vivo mammalian genotoxicity test (micronucleus [MN] assay; OECD [ZIP_CODE]; 
C
omet assay OECD 489)12. 
Four of six formulations tested, including Bold Menthol,  exhibited negative responses in all three 
in vitro assays (Ames, NRU, and MN assays).  Two formulations, including Bold Classic, 
displ
ayed negative responses in the Ames and NRU assays, but required further evaluation in the 
MN assay.  The MN response for the Bold Classic formulation was “equivocal” (values were 
higher for the Bold Classic formulation than the negative control but within the historical control 
values for the assay) whereas the other formulation had a definitive positive response in this in 
vitro assay.  While none of the e-liquid ingredients in these formulations are known mutagens or 
carcinogens, mixtures of e-liquid could potentially trigger in vitro genotoxic responses in cellular 
systems. In the absence of OECD guidelines for tobacco products, we rely on the guidelines for 
pharmaceutical drug candidates which  recommends that in vivo genotoxicity assays  be used to 
further investigate genotoxicity detected by [CONTACT_461964]” (OECD 474/[ZIP_CODE],12).  
Accordingly, ALCS has initiated in vivo genotoxicity testing of Bold Classic and the other 
formulation, using a conservative approach of including two independent endpoints (in vivo MN 
and in vivo Comet responses following acute inhalation exposures of e-liquid aerosols in rats) 
based on the combined OECD guidelines [ZIP_CODE] and [ZIP_CODE].  Preliminary results for the other 
formulation are negative at both endpoints.  The results for the Bold Classic formulation are 
pending, however, it is likely to be negative (to be confirmed) considering a weaker in vitro MN 
response compared to that of the other formulation.   
I
n addition to an in vitro battery of assays, all flavor ingredients were tested as aerosols via in 
vivo 90-day inhalation exposures in rats. While not product formulation specific, these 
investigations allow holistic evaluations of respi[INVESTIGATOR_461921]. ALCS- RA-16-06-EV  
 
 
Page 30 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  inhaling aerosols of e-Vapor flavor mixtures, similar to the human mode of exposure.  
Additionally, Werley et al (2016)[ADDRESS_591383] (MarkTen® CVR1.3) did not show meaningful difference in 
biological endpoints between the vehicle only and the vehicle with flavor groups.  
In conclusion, we believe there is no concern for use of these e-Vapor products in future clinical 
studies based on the above formulation, product-specific testing, and the overall weight-of-
evidence toxicological assessment. Both formulations are currently available in the commercial 
market (since August 8, 2016) based on our initial toxicological assessment.  
Human studies on previous Nu Mark e-Vapor Products 
In-Clinic Human Studies (n=5) 
Pharmacokinetic Studies  
Study 1 
ALCS sponsored three pharmacokinetic (PK) studies of e-Vapor products since 2012. The first 
study (CEL-LIQ-01-12) included two prototype e-Vapor products (CVR1.2 NS [PM [ZIP_CODE]-54-
B
] non-menthol and CVR1.2 MS [PM [ZIP_CODE]-57-A] menthol flavored) containing 2% tobacco-
de
rived nicotine by [CONTACT_8497] (Study number CEL-LIQ-01-12). The purpose of this PK study was 
to 
characterize the nicotine plasma PK profile from single and multiple (1 use [10 inhalations] 
each hour over 12 hours) uses of the prototypes. This randomized, single-blind, 4 period 
crossover PK study was conducted in 27 (14 males, mean age 36.3 years) healthy adult cigarette 
smokers. Subjects were instructed to use the prototype e-Vapor products by [CONTACT_41678] 5-second 
puffs over a 5-minute period, repeating the exposure every hour for 12 hours. Six subjects (25%) 
experienced 11 mild adverse events (AEs) on the day they were using the CVR1.[ADDRESS_591384], 
and 7 subjects (29%) reported [ADDRESS_591385] 
common AE was throat irritation (4 subjects), followed by [CONTACT_41679] (2 subjects), and nausea (2 
subjects). 
Study 2 
The second study (CEL-LIQ-01-13) included two prototype e-cigarette products (CVR1.3 NB3 
[
[ZIP_CODE]-126-NB3%] containing 3.0% tobacco-derived nicotine by [CONTACT_8497] (NBW) and CVR1.3 
NB
5 [[ZIP_CODE]-126-NB5%] containing 5% tobacco-derived NBW). Twelve adult smokers (6 males 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 31 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  and 6 females) participated in the study. For each product, the subjects took ten [ADDRESS_591386] reported six adverse events (AEs) (including dry 
lip, nausea, vomiting, and dizziness) following the use of the CVR1.[ADDRESS_591387], and three 
subjects experienced 15 AEs (including nausea, vomiting, feeling hot, burning sensation, 
dizziness, nervousness and hiccups) following the use of the CVR1.[ADDRESS_591388] study (ALCS-E45-01 -14) included 4 prototype e- Vapor products containing 2.5% to 
4.5 % tobacco-derived nicotine by [CONTACT_8497]. The purpose of the PK study was to characterize the 
nicotine plasma PK profile from single and multiple (1 use each hour over 10 hours) uses of the 
prototypes. Adult subjects were instructed to use the prototype e-Vapor products by [CONTACT_461965] a 10-minute period, repeating the exposure every hour for 10 hours. Five (21%) of the 
[ADDRESS_591389] common AE (11 events in two subjects) was throat irritation, followed by 1 
dry throat, 1 headache and 1 dizziness.  
P
uff Topography studies  
Study 1 
ALCS conducted a study (CRT-LIQ-01-13) to evaluate puffing topography measurements in 
subjects using a prototype e-Vapor product, CVR1.3 (PM-[ZIP_CODE]-87A) (Study number: CRT-
LI
Q-01 -13). Thirteen (6 males) adult cigarette smokers and 10 (4 males) adult e-Vapor users 
were enrolled in this study. Subjects were provided 2 cartridges (2% by [CONTACT_461966]-derived 
nicotine) for ad libitum use over a 7-hour period. Twelve (6 males) of the thirteen cigarette 
smokers returned to the study site for additional puff measurements using 4 prototypes (2% by 
[CONTACT_461966]-derived nicotine). The subjects were instructed to take ten 5 second puffs over a 
5 minute period. The subjects repeated this puff regimen 6 times a day (3 times per prototype) on 
two separate days. One reported AE of headache (mild) was considered possibly related to study 
product. 
Study 2 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 32 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  ALCS sponsored a study (ALCS-M10-05-14) to evaluate puffing topography measurements in 
thre
e different groups of tobacco product users: adult smokers, adult smokers and e-Vapor users 
(dual users) and adult exclusive e-Vapor users.  During the study subjects used CVR1.5 e-Vapor 
products (2.5% tobacco-derived nicotine in both Menthol and Classic flavors) ad libitum over 
eight consecutive hours.  Ninety one generally healthy adult subjects (48 males) were enrolled 
and eighty nine subjects completed the study.   On average, subjects used approximately 2.9 
CVR1.5 e-Vapor cartridges over the 8 hours and no adverse advents were reported.   
Ambulatory Studies (n=2) 
Study 1 
ALCS sponsored an Ambulatory Vapi[INVESTIGATOR_461922] (COV-M10-01-14) in 2014. One 
hundr
ed forty-eight (70 males) healthy adult smokers were enrolled in the randomized control 
study. One hundred and three (48 males) subjects were allowed to smoke their own brand 
conventional cigarettes and use an e-Vapor CVR 1.5 (1.5% tobacco-derived nicotine, either 
Classic or Menthol flavored) product ad libitum and 45 (22 males) smoked their conventional 
cigarettes ad libitum without using e-Vapor products for four weeks. Of the [ADDRESS_591390] products 
by [CONTACT_473] ([ADDRESS_591391] Infection, 1 Throat Irritation and 1 Headache). 
Study [ADDRESS_591392] use study (ALCS-M10-02-14).  Two hundred 
a
nd twenty six (104 males) adult cigarette smokers were randomized into five groups 
investigating the use of cigarettes with the use of CVR1.5 e-Vapor products (1.5% tobacco-
derived nicotine, in Classic [C15] or Menthol [M15] flavor and 2.5% tobacco-derived nicotine in 
Classic [C25] or Menthol [M25] Flavor) for 3 weeks.  Two groups were instructed to use their 
own brand cigarettes and CVR1.5 e-Vapor products (n=51, C15/M15; n=49, C25/M25) ad 
libitum and two groups were instructed to use their own brand cigarettes ad libitum and at least 1 
CVR1.5 e-Vapor cartridge per day (n=52, C15/M15; n=49, C25/M25).  The control group 
(n=25) continued to smoke their own brand cigarettes ad libitum.  A total of 26 subjects (11.5% 
of enrolled subjects) reported [ADDRESS_591393] use groups, 15 mild or moderate AEs from 9 subjects 
(4.0% of CVR1.5 e-Vapor use groups)  were considered as unlikely, possibly or likely related to 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 33 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591394] products by [CONTACT_473] (no definitely related AEs were reported).  Of these [ADDRESS_591395] across all 
of the CVR1.5 use groups was mild oral discomfort (2 subjects, 1% of the CVR1.5 e-Vapor use 
groups).  
Consumer Response Center Data 
ALCS continuously monitors consumer calls to the Consumer Response Center regarding e-
Vapor products currently marketed as MarkTen® e-Vapor since August 2013. As of March 31, 
2016, c
onsumers reported via the Consumer Response Center a total of 538 alleged physical 
effects (APEs) related to the use of e-Vapor products (estimated 26 million cartridges distributed 
to consumer
s). Of the [ADDRESS_591396] common were “burned skin or hair” (42%) 
and other type of APE reports were “sore or burning mouth or tongue or lips” (12%), “sore or 
burning throat” (6%), “coughing” (6%), “nausea or vomiting” (4%), “electrical shock” (4%), 
“headache” (3%), “dizziness or lightheaded” (2%), “after taste” (2%), “blisters in mouth or on 
lips” (2%) and “stomach ache” (2%). There were 30 other APE symptoms each with less than 
2% of the total reports. Majority (74%) of the APEs were categorized as minor. Three of the 
APE reports – “difficulty breathing” (1), “swelling” (1) and “blacking out, fainting or passing 
out” (
1) were categorized as severe.   
Based on the information presented, it is anticipated that Product XLCB and Product XLMB test 
e-Vapor products will be well-tolerated in this study and the subjects will be informed that the 
test e-Vapor products used in this research bear the following warning: 
This 
product is not a smoking cessation product and have not been tested as such. This 
product is intended for use by [CONTACT_41682], and not by [CONTACT_7683], women who 
are pregnant or breast feeding, or persons with or at risk of heart disease, high blood 
pressure, diabetes, or taking medicine for depression or asthma. Nicotine is addictive and 
habit forming, and it is very toxic by [CONTACT_12699], in contact [CONTACT_8124], or if swallowed. 
Nicotine can increase your heart rate and blood pressure and cause dizziness, nausea, and 
stomach pain. Inhalation of this product may aggravate existing respi[INVESTIGATOR_14437]. 
Ingestion of the non-vaporized concentrated ingredients in the cartridges can be poisonous. 
F
or products sold in the State of [LOCATION_004], the following warning will be present at points of 
sale: 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 34 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  CA Proposition 65 WARNING: This product can expose you to chemicals including 
glycidol, which is known to the State of [LOCATION_004] to cause cancer, and nicotine, which is 
known to the State of [LOCATION_004] to cause birth defects or other reproductive harm. For more 
information go to www.P65Warnings.ca.gov. 
Glycidol is detected in the aerosols generated from our products. IARC has classified glycidol as 
“probably carcinogenic to humans (Group 2A)”14. Our scientific test data however show that the 
anticipated human exposures are substantially below the established regulatory limits15 
 Purpose of this Study 1.[ADDRESS_591397] e-Vapor products (Product XLCB or Product B) as compared 
to adult smokers who continue to smoke conventional cigarettes. This study will support the 
ove
rall assessment of the health risk associated with the use of the e-Vapor products in adult 
smokers using e-Vapor products exclusively. 
 H
ypothesis 1.[ADDRESS_591398] been identified in cigarette smoke3, many of these chemicals 
are present either in the particulate or gas/vapor phase of the smoke aerosol. The test e-vapor 
products do not produce the vast majority of these compounds, therefore switching from 
cigarettes to the test e-vapor products should result in large reductions in exposure to many of the 
chemicals present in cigarette smoke.  However we have no evidence of the impact of switching 
from cigarettes to the test e-vapor products. This study is designed to measure changes in 
biomarkers of exposure and biomarkers of potential harm when adult smokers switch to the test 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 35 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591399]   
2.0 S
TUDY OBJECTIVES 
 Primary Objective 2.1
The primary objective of this study is to compare absolute changes in selected biomarkersa from 
Baseline to End of Study (EOS) between adult smokers who continue to smoke conventional 
cigarettes (Control group ) ad libitum and adult smokers who have completelyb switched to ad 
libitum use of the test e-Vapor products (Test groups) for 12 weeks.  
a S
eleted biomarkers include: 
 W hite Blood Cell Count (WBC) 
 High Density Lipoprotein Cholesterol (HDL-C )  
 Urinary 8-epi-prostaglandin F 2α 
 Urinary 11 Dehydrothromboxane B 2 
 B lood Soluble Intercellular Adhesion Molecule-1 (sICAM-1)  
 Ur inary 4-(methylnitrosamino)-1- (3- pyridyl)-1-butanol and its glucuronides (total 
NN
AL)  
 C arboxyhemoglobin (COHb )  
b Subjects who exclusively use e-Vapor products and with eCO measurements < 8 ppm from 
Week 3 through EOS 
 Secondary Objectives 2.2
The secondary objectives are to: 
 C ompare changes in selected biomarkers (same as those in the primary objective) from 
Baseline to Week [ADDRESS_591400] and Control groups  
 Determine the number of cigarette s smoked (Test and Control groups) from Week 2 through 
EOS 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 36 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Assess changes in the amount of test e-Vapor product use (Test groups only) from Week 2 
through EOS  
 Asse ss adherence to protocol by [CONTACT_461967] 2.3
The exploratory objectives are to: 
 Asse ss changes in BOPHs and BOEs (same as in the primary objective) from Baseline to 
Week 6  and EOS in two subgroups that use different flavored e-Vapor products  
 Assess changes in forced expi[INVESTIGATOR_104763] (FEV 1), forced vital capacity 
(FVC) and FEV 1/FVC ratios from Screening/Visit [ADDRESS_591401] and Control 
groups 
 Assess changes in urine nicotine equivalents ( NE) from Baseline to Week [ADDRESS_591402] and Control groups 
 Assess changes in the QGEN and TQOLIT questionnaires and the Cough Questionnaire from 
B
aseline to EOS with in the Test and Control groups 
 Asse ss reasons for test product use/not-use at EOS and mCEQ from Baseline to EOS for the 
Test groups 
 C ollect blood and urine samples for future assessment of BOE and or BOPH 
3.0 SUMMARY OF STUDY DESIGN 
 Design 3.1
This research study will utilize a randomized, parallel-group, open-label, controlled design and 
will be conducted at multiple study sites. Up to 450 adult male and female (neither gender should 
account for more than 60% of the population) smokers (30 years of age to 65 years of age, 
inclusive) with ≥ 10 years of smoking and an average daily cigarette consumption of ≥ 10 CPD 
during the 12 months prior to Screening, Visit 1 will be randomized into one of the three study 
g
roups on Day 1. Subjects that pass the initial screening at Visit 1 (Screen Part 1) will be asked 
to return to the study site for a test product trial at Visit 2 (Screen Part 2). During the Test 
product trial, potential subjects will be allowed to use each of the Test Products for [ADDRESS_591403] Assessment 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 37 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591404] products will be randomized at Visit 3 (Day 1) to one of the study 
groups.  
 
 C ontrol Group (n=150):  Continue smoking under ad libitum use of subjects’ own brand 
of conventional lit-end cigarettes, without use of any other type of tobacco/nicotine 
containing product, for the entire 12 weeks 
 Test 1 Group (n=150): Stop smoking during Week [ADDRESS_591405] e-Vapor 
products (Product XLCB), without use of any other type of tobacco/nicotine containing 
product, for the entire 12 weeks 
 Te st 2 Group (n=150): Stop smoking during Week [ADDRESS_591406] e-Vapor 
products (Product XLMB), without use of any other type of tobacco/nicotine containing 
product, for the entire [ADDRESS_591407] the study at randomization 
(e.g., because they do not wish to continue in the group into which they were randomized); such 
subjects will be replaced. 
All subjects will report their cigarettes per day (CPD) (Control and Test groups) and Test 
product use (Test groups only) daily using a Short Message Service (SMS), i.e., text message, 
based system (Med-Quest) . Subjects in the Test groups are allowed up to 1 week (Day 1 through 
Day 7) to acclimatize to switching to the Test Product. By [CONTACT_2006] 8, all subjects in the Test group 
will
 have completely switched to exclusive use of the Test Product without use of any other 
tobacco or nicotine products until the end of the study. The self-reported CPD, use of other 
tobac
co products, and eCO measurements, taken during the in-clinic visits after randomization 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 38 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591408] safety. Screening safety evaluations will include the following: 
physical examination; vital signs; body weight and height; body mass index (BMI); 12-lead 
electrocardiogram (ECG); human immunodeficiency virus (HIV), hepatitis B surface antigen 
(HbsAg), hepatitis C virus (HCV) serology; clinical chemistry, hematology, and urinalysis; lung 
function (FEV1, FVC, and FEV1/FVC ratio); and pregnancy testing (all females ). Visit 3 safety 
evaluations will include the following: physical examination (symptom driven); vital signs; body 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 39 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  weight; BMI; and pregnancy testing (all females ). Visits 4, 5 and 6, safety evaluations will 
include vital signs. Visit 7/EOS (or early termination) safety evaluations will include a ph ysical 
examination (symptom driven); vital signs; body weight; BMI; 12-lead electrocardiogram 
(E
CG); clinical chemistry, hematology, and urinalysis; and pregnancy testing (all females ). 
AEs 
will be monitored and recorded from the time of the test e-Vapor product trial at Screening 
P
art 2, Vis it 2 until the End of Study (or upon Early Termination). Events occurring after 
infor
med consent signing and before the test e-Vapor product trial will be recorded and 
c
onsidered baseline signs and symptoms.  
An
y concomitant medications taken from 30 days prior to Screening, Visit 1 through the End of 
Study (or upon Early Termination) will also be recorded. 
4.[ADDRESS_591409]: 
 
1) sig
n an IRB-approved informed consent form (ICF) for the study; 
2) be between the ages of 30 and 65 years, inclusive, at the time of Screening, Visit 1; 
3) have > 500 ng/ml urine cotinine measurement at screening Visit 1; 
4) have smoked for ≥10 years and smoked an average of ≥ 10 manufactured cigarettes per day 
during the 12 months prior to Screening, Visit 1; 
a) Brief
 periods [i.e., up to 7 consecutive days] of non-smoking during the 12 months prior to 
S
creening, Visit 1 due to illness, trying to quit, participation in a study where smoking was 
pr
ohibited are acceptable.  
5) indi
cate that he/she is “definitely” or “probably” willing and able to replace their cigarettes 
for [ADDRESS_591410];  
6) ha
ve daily access to text messaging capable cellular phone for daily product use reporting ;  
7) have a negative ethanol breath test and amphetamines, opi[INVESTIGATOR_858], cannabinoids, and cocaine 
ur
ine drug screen results at Screening, Visit 1;  
a) Subjects with a prescription from a licensed physician will not be exempted from thi s 
criterion. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 40 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  8) if female ( all females), have a negative serum pregnancy test at Visit [ADDRESS_591411] at Visit 2 through Visit 7, inclusive;  
9) if female, heterosexually active, and of childbearing potential (i.e., not surgically sterile or 2 
years naturally postmenopausal), must have used a medically accepted method of contraception 
(list
ed below in a) and b)) prior to Screening, Visit [ADDRESS_591412] agree to continue to use such 
method(
s) through the End of Study;  
a) Surgically sterile includes bilateral tubal ligation, Essure, hysterectomy, or bilateral 
oophorectomy at least 6 months prior to Screening, Visit 1. Naturally postmenopausal is defined 
a
s women having 2 years without menses. 
b) Acceptable methods of contraception are: hormonal (i.e., oral, transdermal patch, implant, or 
injection) consistently for at least 3 months prior to Screening, Visit 1; double barrier (i.e., 
c
ondom with spermicide or diaphragm with spermicide) consistently for at least 2 weeks prior to 
S
creening, Visit 1; and intrauterine device for at least 3 months prior to Screening, Visit 1; or 
onl
y have a partner who has been vasectomized for at least 6 months prior to Screening, Visit 1. 
10) B
e willing and able to comply with the requirements of the study. 
 E
xclusion Criteria 4.[ADDRESS_591413]. Any exceptions will be 
doc
umented.  
 
1) Hist
ory or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, 
hematologic, endocrine, oncologic, urologic, diabetes, existing respi[INVESTIGATOR_3748], 
immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opi[INVESTIGATOR_18959], would jeopardize the safety of the subject or impact the validity of the study 
results. (Note: chronic medical conditions controlled and on stable medications [over past 3 
mon
ths] may not be exclusionary per Investigator discretion);  
2) Currently taking medication for depression, asthma or diabetes; 
3) Allergy to menthol; 
4) Systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg at 
S
creening Visit 1; 
5) Ha
ve clinically significant abnormal findings on the physical examination, vital signs, 
electrocardiogram (ECG), or medical history that would jeopardize the safety of the subject, in 
the opi[INVESTIGATOR_689];  
6) Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), 
or hepatitis C virus (HCV) at Screening, Visit 1; 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 41 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  7) Current evidence or any history of congestive heart failure; 
8) Any acute illness (e.g., upper respi[INVESTIGATOR_4416], viral infection) requiring treatment 
within 2 weeks before Visit 3 (Day 1); 
9) Hist
ory of drug or alcohol abuse within 24 months of Visit 3 (Day 1) as defined by [CONTACT_941] 
I
nvestigator; 
10) BMI greater than 40.0 kg/m2 or less than 18.0 kg/m2 at Screening, Visit 1; 
11) P
ost-bronchodilator FEV 1:FVC ratio < 0.7 and FEV 1 < 50% of predicted at Screening,    
Visi
t 2; 
12) Post-bronchodilator FEV1:FVC ratio < 0.75 and FEV1 increase ≥ 12% and  > [ADDRESS_591414]-bronchodilator at Screening, Visit 2; 
13) Esti
mated creatinine clearance (by [CONTACT_3158]-Gault equation) < 80 mL/min at Screening, 
Visit 1; 
14) Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 1.5 times 
the upper limit of the reference range at Screening, Visit 1; 
15) Female candidates who are pregnant, lactating, or intend to become pregnant from 
Screening, Visit 1 through End of Study; 
16) Use of HDL-C raising medication / supplements (e.g., niacin, gemfibrizole, fenofibrate, etc.) 
within the past 3 months prior to Screening, Visit 1 or any time during the study; 
17) Use
 of nicotine-containing products other than manufactured cigarettes (e.g., roll-your-own 
cigar
ettes, e-cigarette or e-Vapor products, Bidis, snuff, nicotine inhaler, pi[INVESTIGATOR_5836], cigar, smokeless 
tobac
co, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) within 14 days prior to 
S
creening, Visit 1 through Visit 3 (Day 1) except as required for the purpose of this study; 
18) Dona
tion of blood or blood products, including plasma, history of significant blood loss in 
the opi[INVESTIGATOR_461923], or receipt of whole blood or a blood product transfusion within 
60 da
ys prior to Visit 3 (Day 1); 
19) Participation in a clinical study of an investigational drug, medical device, biologic, or of a 
tobac
co product, within 30 days before Visit 3 (Day 1); 
20) Participation in more than two ALCS studies within 12 months before Visit 3 (Day 1); 
21) Already enrolled or failed screening for the current study at a different study site; 
22) Subject or a first-degree relative (i.e., parent, spouse, sibling, or child) is a current or former 
e
mployee of the tobacco industry or a named party or class representative in litigation with an y 
tobacco company. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 42 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Restrictions  4.3
 No participation in other studies or blood donations (other than for this study) or plasma 
while taking part in this study.  
 S ubjects will be instructed not to use any tobacco or nicotine-containing products other 
than manufactured cigarettes and/or test e-Vapor product (according to their group 
a
ssignment) (e.g., roll-your-own cigarettes, e-cigarette or e-Vapor products, Bidis, snuff, 
nicotine inhaler, pi[INVESTIGATOR_5836], cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine 
lozenge, or nicotine gum) following randomization. 
 Medic ations with therapeutic effect on HDL-C, or medications for for depression, asthma 
or diabetes, are not allowed during the study. 
 Conco
mitant Medications 4.4
Any concomitant medications taken from 30 days prior to Screening, Visit 1 through the End of 
S
tudy (or upon Early Termination) will be recorded. 
Stable doses (i.e., no dosage adjustments within 3 months prior to Screen, Visit 1) of prescription 
or
 over-the-counter medications required to treat an Investigator-approved disease or condition 
(e.g., hypertension) are permitted at the discretion of the Investigator. Hormonal contraceptives 
(e.g., oral, transdermal patch, implant, injection) and hormonal replacement therapy are 
permitted. Occasional use of over-the-counter analgesics (e.g., acetaminophen, ibuprofen), 
antihistamines, and nasal decongestants are permitted. Exceptions may be permitted at the 
discretion of the Investigator in consultation with the Sponsor or designee, providing the 
medication in question would have no impact on the study. Any exceptions will be documented.  
5.[ADDRESS_591415] e-Vapor Products 5.1
• Product XLCB = Test EVP (currently marketed by [CONTACT_41677]® XL Bold 
Classic [4.0% NBW]) [CVR2.6.8] Formula: [ZIP_CODE]-44 -B; Name: “Rosetta”; Label: B44 
• Product XLMB = T est EVP (currently marketed by [CONTACT_41677]® XL Bold 
Menthol [4.0% NBW]) [CVR2.6.8] Formula: [ZIP_CODE]-40-E; Name: “Spencer”; Label: 40E 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 43 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591416] XLCB for the Rosetta (Bold Classic) flavor 
and Product XLMB for the Spencer (Bold Menthol) flavor in this study. Each test e-Vapor 
product consists of a battery and a cartridge. Each cartridge contains approximately 32 mg 
solut
ion consisting of propylene glycol, glycerol, flavors, and 4.0% USP grade tobacco-derived 
nicotine by [CONTACT_8497]. Once the battery is close to being fully discharged, the LED will blink 
indicating that the battery needs to be recharged. When a cartridge is almost empty there is a 
noticeable reduction in vapor and flavor. 
 Study Material Accountability 5.[ADDRESS_591417] 
e-Vapor products will be kept at controlled room temperature (defined as 20˚-25˚C [68˚ - 77˚F], 
with excursions permitted to 15˚C - 30˚C [59˚ - 86˚F] for up to 15 minutes ).  
The study site will document and reconcile the total number of test e-Vapor products shipped to 
the stud
y site, the total number of test e-Vapor products dispensed, the total number of used test 
e-
Vapor p roducts collected during the study, and the total number of unused test e-Vapor 
products remaining at the end of the study.  
I
t is the responsibility of the Investigator to ensure that a current record of test e-Vapor product 
accountability is maintained at each study site where test e-Vapor product is inventoried and 
dispensed. Records or logs must include: 
• Number received/placed in storage area 
• Date dispensed 
• Amount dispensed to and returned by [CONTACT_6992], including unique subject identifiers 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 44 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  • Amount re-dispensed to each subject, including unique subject identifiers 
• Number dispensed but not returned (e.g., lost by [CONTACT_1130]) 
• Amount returned to Sponsor 
I
ndividual test e-Vapor product dispensing records will be maintained by [CONTACT_461968]. Test e-Vapor products will be prepared for use by [CONTACT_461969].  
Upon 
completion or termination of the study, all used and unused test e-Vapor products will be 
re
conciled at the study site. The test products will then be returned to ALCS or designee (return 
address and instruction will be provided separately). Twenty-four cartridges (one box) of each lot 
of
 flavored test e-Vapor product will be retained by [CONTACT_461970] (even if within [ADDRESS_591418] expi[INVESTIGATOR_1516]). 
All 
test e-Vapor products returned to ALCS or designee must be accompanied by [CONTACT_461971][INVESTIGATOR_7788]. If test product is returned and never dispensed to subjects, the supply should 
be
 in the original packaging.  
 Study Material Dispensing 5.[ADDRESS_591419] identifiers, date it was 
dispensed, the statements of “For study use only , not for sale” and “Keep out of reach of 
c
hildren”.  
Subjects should be reminded at Visit 3/Day 1, Visit 4/Week 3, Visit 5/Week 6, and Visit 6/Week 
9, when test e-Vapor products are distributed, to keep test e-Vapor products out of the reach of 
children and that they must keep all used and unused cartridges from the time of dispensing until 
the next visit and bring them to the study site at the following visit.  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 45 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591420] (Test and Control groups) will be documented 
by [CONTACT_461972] 1. Photocopi[INVESTIGATOR_461924] [ADDRESS_591421]’s regular cigarette has changed. There will be no restrictions on cigarette 
brand at any time during the study. 
6.0 VISIT 1, SCREENING PART 1 (DAY -28 TO DAY -7) 
 A
ge Verification and Photocopy of ID  6.[ADDRESS_591422] show proof of age with government-issued ID (e.g., driver’s license) which 
will be photocopi[INVESTIGATOR_41658]. 
 Informed Consent 6.[ADDRESS_591423] the study explained by [CONTACT_21438]/her designee. 
All prospective subjects will be required to read, sign, and date the study informed consent form 
(ICF) prior to any screening/study procedures being performed. Written acknowledgment of the 
receipt of the full informed consent and the subject’s freely tendered offer to participate will be 
obtained from each subject in the study and documented in the source documents. Each subject 
will receive a signed and dated copy of his/her ICF. 
 Medical History 6.[ADDRESS_591424]. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 46 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Demographics and Tobacco Use History Questionnaires 6.4
Subjects will fill out the Demographics and Tobacco Use History Questionnaires 
(APPENDECES 
Appendix 1). 
 Re
view Inclusion / Exclusion Criteria 6.[ADDRESS_591425] been met. Subjects 
who do not meet the inclusion/exclusion criteria will be considered screen failures; data to be 
captured will include subject demographics and the reason(s) for screen failure. 
 Vital S
igns 6.[ADDRESS_591426] conventional cigarette smoked.  
 Body Weight, Height, and Body Mass Index 6.7
Height (meters) and weight (kg) will be measured in indoor clothing without shoes. BMI will be 
calculated as weight (kg)/height (meters) squared (kg/m2). 
 Smoking Cessation Information 6.[ADDRESS_591427]™ brochure or referral to the Quit Assist™ web site, 
whic
h contains citations to a number of third-party information sources, including web sites, 
tele
phone resources, and other organizations with additional information. 
 Clinical Laboratory Tests 6.9
All clinical laboratory tests will be conducted by a central laboratory facility accredited by [CONTACT_461973] (Clinical Laboratory Improvement Amendments of 
1988 [CLIA-88]) or at the clinic study site using CLIA-waived kits or procedures. Values for the 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 47 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591428] positive for alcohol and/or drugs will be considered screen failures and will not complete the 
remaining screening assessments at this visit (with the exception of the Demographics and 
Tobacco Use History questionnaire).  
6.9.[ADDRESS_591429], blood urea nitrogen (BUN), alkaline phosphatase, total 
bilirubin, glucose, creatinine (at screening, creatinine clearance will be calculated using 
Cockcroft-Gault formula), total protein, uric acid, and albumin. 
6.9.[ADDRESS_591430] 8 hrs fasting, consisting of hemoglobin, hematocrit, 
red blood cell count (RBC), white blood cell count (WBC) with differential, and platelet count. 
6.9.4 Ur inalysis 
Routine clinical urinalysis consisting of bilirubin, blood, glucose, ketones, leukocyte esterase, 
nitrite, pH, protein, specific gravity, and urobilinogen will be evaluated. Microscopic 
examination will be conducted if protein, leukocyte esterase, nitrite and/or blood are detected. 
Microscopic analysis will include RBC, WBC, casts, and bacteria.  
6.9.[ADDRESS_591431] for HIV, HbsAg, and HCV will also be performed. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 48 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591432] (Females) 
Serum pregnancy test will be performed for all  female subjects. 
 Re
view of Concomitant Medications 6.10
Any concomitant medications taken from 30 days prior to Screening Part 1, Visit 1 will be 
re
corded. 
 Review of Tobacco and Nicotine Restrictions 6.11
Subjects will be given instructions regarding permissible tobacco and nicotine containing 
products for this study and the study site staff will advise the subjects of the importance of 
compliance with study instructions. 
7.0 VISIT 2, SCEENING PART 2 (AFTER ASSE SSMENT OF SCREENING PART 1 AND 
ON OR BEFORE DAY -5) 
 Re
view Inclusion / Exclusion Criteria 7.1
Brief written assessment (medical/medication questionnaire) to affirm that the inclusion and 
exclusion criteria/restrictions have not been violated since Screening Visit 1. Subjects who do 
not meet the inclusion/exclusion criteria will be considered screen failures; data to be captured 
will include subject demographics and reason(s) for screen failure. 
 Vital S
igns 7.[ADDRESS_591433] used.  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 49 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Physical Examination 7.3
General physical exam including observations and questioning by [CONTACT_21438]/h er 
qualified designee. 
 12-Lead ECG 7.[ADDRESS_591434] 
result will continue to be eligible. 
 Spi[INVESTIGATOR_038] 7.6
All subjects will undergo spi[INVESTIGATOR_75037] (FEV1, FVC, and FEV1/FVC ratio) at the study site. 
Spi[INVESTIGATOR_235719] 2005 American Thoracic 
Society / European Respi[INVESTIGATOR_235720]. 
The spi[INVESTIGATOR_461925] a study specific spi[INVESTIGATOR_461926] a central 
vendor. The spi[INVESTIGATOR_461927]. Study site staff performing spi[INVESTIGATOR_461928]. The quality of the tests will be reviewed by a 
centralized over-reader, however, the evaluation of the spi[INVESTIGATOR_461929]. The spi[INVESTIGATOR_461930] e-Vapor product use and in sitting 
position. The subjects will be instructed on how to correctly perform spi[INVESTIGATOR_461931]. Spi[INVESTIGATOR_461932] a short-acting bronchodilator (albuterol). 
Following acceptable pre-bronchodilator measurements, subjects will be administered 4 puffs 
from an albuterol metered-dose inhaler at 30 second intervals (~360 µg total dose assuming 90 
µg per puff) using a spacer and a 5-second breath hold after each puff. Post-bronchodilator 
measurements will be made approximately [ADDRESS_591435] albuterol puff. 
Spi[INVESTIGATOR_461933]. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 50 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Review of Concomitant Medications 7.7
Subjects will be asked about any medications they are taking and the results will be documented.  
 Confirm Cigarette Brand / Photocopy Cigarette Pack 7.[ADDRESS_591436]’s brand name [CONTACT_461993] a color photocopy of the pack will be made.  
 Review
 of Tobacco and Nicotine Restrictions 7.[ADDRESS_591437] trial 7.10
Subjec
ts will use both the Rosetta (Bold Classic) and Spencer (Bold Menthol) test e-Vapor 
products (for approximately [ADDRESS_591438] use), following an assigned sequence in an open label fashion (i.e., subjects 
will be informed of the flavors of the product that he/she is using). Study personnel will alternate 
be
tween administering each subject with the Rosetta (Bold Classic) or Spencer (Bold Menthol) 
flavor first (e.g., Subject 1: Spencer (Bold Menthol) – Rosetta (Bold Classic), Subject 2: Rosetta 
(B
old Classic) – Spencer (Bold Menthol), Subject 3: Spencer (Bold Menthol) – Rose tta (Bold 
Classic), etc).   
 T
est e-Vapor Product Assessment  Questionnaire  7.[ADDRESS_591439] Assessment Questionnaire (Appendix 4) on both of the test e-
Vapor products following completion of product trial (Section 7.10).  
S
ubjects that pass all other eligibility requirements and indicate they would “definitely” or 
“probably” be willing and able to replace their cigarettes with a t est e-Vapor product for the 
dura
tion of the study will be eligible for enrollment.  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 51 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591440] trial until the End of Study (or upon 
Early Termination) must be recorded in the eCRF. Events that occur after informed consent 
signing and before the test e-Vapor product trial will be recorded in the eCRF and considered 
baseline signs and symptoms.  
 Subject Instructions for Product Use 7.[ADDRESS_591441] subjects on collection, storage, and returning 
the sa
mple at the subsequent visit; subjects will be instructed that urine collection should occur at 
least [ADDRESS_591442] their collection materials will be 
required to return to the clinic for additional supplies prior to the collection days. 
 Reminder Calls 7.15
Study site personnel should make a phone call within 24 – 72 hours to subjects prior to their 
Visi
ts to remind them the date and time of the visits (Visits 3 – 7), and collecting and bringing 
the 
first void of day urine samples to study site and fasting for at least 8 hours prior to the study 
visit (Visits 3, 5 and 7).  Subjects should be reminded to maintain their usual smoking/vapi[INVESTIGATOR_461934]; abstinence is not required. 
8.0 VISIT 3, BASELINE, RANDOMIZATION (DAY 1) 
Visi
t 3 should be arranged in the morning to accommodate fasting blood sampling. Subjects 
should be reminded to maintain their usual smoking behavior during the morning of the study 
visit; abstinence is not required. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 52 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Review of Inclusion / Exclusion Criteria 8.1
A brief assessment (medical/medication questionnaire) to affirm that the applicable inclusion and 
exclusion criteria/restrictions have not been violated since the Screening Visits will be 
performed. Subjects who do not meet the inclusion/exclusion criteria required at Visit 3 (Day 1) 
will
 be considered screen failures; data to be captured will include subject demographics and 
reason(s) for screen failure. 
 Vital S
igns 8.[ADDRESS_591443] used. 
 Body Weight and Body Mass Index 8.3
Weight (kg) recorded in indoor clothing without shoes. BMI will be calculated as weight 
(kg)/height (meters) squared (height from Screening, Visit 1 will be used to calculate BMI ). 
 P
hysical Examination (Symptom Driven) 8.[ADDRESS_591444] 
result will continue to be eligible. 
 Review of Concomitant Medications 8.6
The study site staff will document any concomitant medications taken by [CONTACT_1766]. 
 Re
view of Tobacco and Nicotine Restrictions 8.7
Subjects will be asked about any tobacco / nicotine containing products they are using and the 
results will be documented. If non-permissible tobacco or nicotine containing products have been 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 53 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591445] be recorded in the eCRF. 
 Conf
irm Cigarette Brand / Photocopy Cigarette Pack 8.[ADDRESS_591446]’s brand name [CONTACT_461994] a new color photocopy of the pack will be made, if 
applicable.  
 QGEN and TQOLIT questionnaires (before product use – Day 1 only )  8.10
S
ubjects will complete the QGEN and TQOLIT questionnaires (Appendix 2).  
 Cough
 Questionnaire (before product use – Day 1 only )  8.11
S
ubjects will complete the Cough Questionnaire (Appendix 3 ). 
 m
CEQ Questionnaire 8.12
S
ubjects will complete the appropriate mCEQ Questionnaire (Appendix 5b ). 
 Subject Randomization 8.[ADDRESS_591447] use, subjects will be randomized (stratified by [CONTACT_44207], gender, and age) into one of 
the following randomization groups (n=450 ): 
• Test 1 Group (n=150): Exclusive ad libitum use of test e-Vapor product (Product XLCB), for 
the e
ntire 12 weeks  
• Test 2 Group (n=150): Exclusive ad libitum use of test e-Vapor product (Product XLMB), 
for
 the entire 12 weeks  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 54 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  • Control Group (n=150): Continue to smoke ad libitum subject’s own brand lit-end 
conventional cigarettes, without use of any other type of tobacco/nicotine containing product , 
for the entire [ADDRESS_591448] the reason for drop out; such subjects will be replaced. 
 T
est e-Vapor Product Dispensation  8.[ADDRESS_591449] of 3 batteries, 3 
ba
ttery chargers and a 3-week supply of cartridges (66  cartridges assuming 3 per day ).  Subjects 
should be instructed to contact [CONTACT_461974][INVESTIGATOR_461935].  All test e-Vapor product 
dispensed and returned must be documented by [CONTACT_3452].  
Prior to dispensing, the study site will ensure the test e-Vapor product packaging is labelled to 
disclose, at minimum, the protocol number and unique subject identifiers, date it was dispensed, 
the statements of “For study use only, not for sale” and “Keep out of reach of children”.  
S
ubjects will be asked to bring back all used and unused products (cartridges) at each subsequent 
study visit. Study sites will perform accountability on the returned product.    
Onl
y unused cartridges with the seal intact and at least [ADDRESS_591450] preferably between 
15 and 25oC (59 – 77 oF) and not to leave the product(s) in extreme conditions (e.g. in a car 
parked in the heat/cold, freezer, etc.). 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 55 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591451] use reporting will begin on Day 1. 
 E
xhaled CO Measurement 8.17
Exhaled CO (eCO) measurements will be performed by [CONTACT_461975]+ basic™ 
Smokerlyzer® monitor (coVita). Study site staff performing eCO tests must receive appropriate 
tra
ining. The subjects will be instructed on how to correctly perform the tests prior to the 
measurements being recorded by [CONTACT_144740]. 
 BOE and BOPH Urine Sample Collection (before dispensing study product) 8.[ADDRESS_591452] urine void of the day, between 4:00am 
and 7:00am, and at least 4 hours after the prior void, in the dispensed container as instructed and 
bring it with them to the study site. Sample should be kept refrigerated until packed for transport 
to 
the study site. An ice pack should be placed in the package with the urine sample at the same 
time. Upon receipt, study staff should document the volume (mL) of the urine sample, status of 
the ice pack (present – not/or partially melt ed; pr esent –  fully melt ed; not present). 
Blood Collection for BOPH and COHb 
B
lood will be collected after overnight fasting (at least 8 hrs).  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 56 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  9.0 VISIT 4 (WEEK 3 / DAY 21 ± 3) 
Subjects should be reminded to maintain their usual smoking/vapi[INVESTIGATOR_461936]; abstinence is not required. 
 Review of Inclusion / Exclusion Criteria 9.1
A brief assessment (medical/medication questionnaire) to affirm that the applicable inclusion and 
exclusion criteria/restrictions have not been violated since the Screening Visits will be 
performed. 
 Vital Signs 9.[ADDRESS_591453] 
result will continue to be eligible. 
 Review of Concomitant Medications  9.4
The study site staff will document any concomitant medications taken by [CONTACT_1766]. 
 Re
view of Tobacco and Nicotine Restrictions 9.5
Subjects will be asked about any tobacco / nicotine containing products they are using and the 
results will be documented. If non-permissible tobacco or nicotine containing products have been 
used, the study site staff will remind the subjects of the importance of compliance with study 
instructions. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 57 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591454] be recorded in the eCRF. 
 Conf
irm Regular Cigarette Brand / Photocopy Cigarette Pack 9.[ADDRESS_591455]’s regular brand of cigarettes (Control group) has 
not changed. If the regular brand has changed, the change will be documented and a photocopy 
of the pack made. 
 Test e-Vapor Product Collection  9.[ADDRESS_591456] and document all used and unused products (cartridges). The 
study site will perform accountability on the returned product. 
 T
est e-Vapor Product Dispensation  9.[ADDRESS_591457] until they return to the study site at Visit 5 based on previous use (estimated to be 
approximately 3 batteries, 3 battery chargers and 66 cartridges assuming 3 per day ).  Subjects 
should be instructed to contact [CONTACT_461974][INVESTIGATOR_461937]. All test e-Vapor 
product dispensed and returned must be documented by [CONTACT_3452].  
Prior to dispensing, the study site will ensure the test e-Vapor product packaging is labelled to 
disclose, at minimum, the protocol number and unique subject identifiers, date it was dispensed, 
the statements of “For study use only, not for sale” and “Keep out of reach of children”.  
S
ubjects will be asked to bring back all used and unused products (cartridges) at each subsequent 
study visit. Study sites will perform accountability on the returned product.   
Unused cartridges may be re-dispensed to the same subject. Only unused cartridges with the seal 
intact and at least [ADDRESS_591458]. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 58 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591459] preferably between 
15 and 25oC (59 – 77 oF) and not to leave the product(s) in extreme conditions (e.g. in a car 
parked in the heat/cold, freezer, etc.). 
 Exhaled CO Measurement 9.[ADDRESS_591460] groups with exhaled CO measurements >[ADDRESS_591461] groups with 
exhaled CO measurements >[ADDRESS_591462] subjects on collection, storage, and returning the sample at the subsequent 
visit; subjects will be instructed that urine collection should occur at least 4 hours after the prior 
void. 
10.0 VISI
T 5 (WEEK 6 / DAY 42 ± 3) 
Visi
t 5 should be arranged in the morning to accommodate fasting blood sampling. Subjects 
shoul
d be reminded to maintain their usual smoking/vapi[INVESTIGATOR_461938]; abstinence is not required. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 59 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Review of Inclusion / Exclusion Criteria 10.1
A brief assessment (medical/medication questionnaire) to affirm that the applicable inclusion and 
exclusion criteria/restrictions have not been violated since the Screening Visits will be 
performed. 
 Vital Signs 10.[ADDRESS_591463] 
result will continue to be eligible. 
 Review of Concomitant Medications  10.4
The study site staff will document any concomitant medications taken by [CONTACT_1766]. 
 Re
view of Tobacco and Nicotine Restrictions 10.5
Subjects will be asked about any tobacco / nicotine containing products they are using and the 
results will be documented. If non-permissible tobacco or nicotine containing products have been 
used, the study site staff will remind the subjects of the importance of compliance with study 
instructions. 
 Review of Adverse Events 10.[ADDRESS_591464] be recorded in the eCRF. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 60 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Confirm Regular Cigarette Brand / Photocopy Cigarette Pack 10.[ADDRESS_591465]’s regular brand of cigarettes (Control group) has 
not changed. If their regular brand has changed, the change will be documented and a photocopy 
of the pack made. 
 QGEN and TQOLIT questionnaires  10.8
Subjects will complete the QGEN and TQOLIT questionnaires (Appendix 2).  
 Cough
 Questionnaire  10.9
Subjects will complete the Cough Questionnaire (Appendix 3). 
 T
est e-Vapor Product Collection  10.[ADDRESS_591466] and document all used and unused products (cartridges) at each 
study visit. The study site will perform accountability on the returned product. 
 Te
st e-Vapor Product Dispensation  10.[ADDRESS_591467] until they return to the study site at Visit 6 based on previous use (estimated to be 
a
pproximately 3 batteries, 3 battery chargers and 66  cartridges assuming 3 per day ).  Subjects 
should be instructed to contact [CONTACT_461974][INVESTIGATOR_461935].  All test e-Vapor product 
dispensed and returned must be documented by [CONTACT_3452].  
Prior to dispensing, the study site will ensure the test e-Vapor product packaging is labelled to 
disclose, at minimum, the protocol number and unique subject identifiers, date it was dispensed, 
the statements of “For study use only, not for sale” and “Keep out of reach of children”.  
S
ubjects will be asked to bring back all used and unused products (cartridges) at each subsequent 
study visit. Study sites will perform accountability on the returned product.    
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 61 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591468] preferably between 
15 and 25oC (59 – 77 oF) and not to leave the product(s) in extreme conditions (e.g. in a car 
parked in the heat/cold, freezer, etc.). 
 Exhaled CO Measurement 10.[ADDRESS_591469] groups with exhaled CO measurements >[ADDRESS_591470] groups with 
exhaled CO measurements >[ADDRESS_591471] urine void of the day, between 4:00am 
a
nd 7:00am, at least 4 hours after the prior void, in the dispensed container and bring it with 
them to the study site. Sample should be kept refrigerated until packed for transport to the study 
site. An ice pack should be placed in the package with the urine sample at the same time. Upon 
receipt, study staff should document the volume (mL) of the urine sample, status of the ice pack 
(present – not/or partially melted; present – fully melted; not present).  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 62 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   BOPH and COHb Blood Sample Collection 10.15
Blood Collection for BOPH and COHb 
B
lood will be collected after overnight fasting (at least 8 hrs).  
11.0 VISI
T 6 (WEEK 9 / DAY 63 ± 3) 
S
ubjects should be reminded to maintain their usual smoking/vapi[INVESTIGATOR_461936]; abstinence is not required. 
 Review of Inclusion / Exclusion Criteria 11.1
A brief assessment (medical/medication questionnaire) to affirm that the applicable inclusion and 
exclusion criteria/restrictions have not been violated since the Screening Visits will be 
performed. 
 Vital Signs 11.[ADDRESS_591472] 
result will continue to be eligible. 
 Review of Concomitant Medications  11.4
The study site staff will document any concomitant medications taken by [CONTACT_1766]. 
 Review of Tobacco and Nicotine Restrictions 11.5
Subjects will be asked about any tobacco / nicotine containing products they are using and the 
results will be documented. If non-permissible tobacco or nicotine containing products have been 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 63 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591473] be recorded in the eCRF. 
 Conf
irm Regular Cigarette Brand / Photocopy Cigarette Pack 11.[ADDRESS_591474]’s regular brand of cigarettes (Control group) has 
not changed. If the regular brand has changed, the change will be documented and a photocopy 
of the pack made. 
 Test e- Vapor Product Collection  11.[ADDRESS_591475] and document all used and unused products (cartridges) at each 
study visit. The study site will perform accountability on the returned product. 
 Te
st e-Vapor Product Dispensation  11.[ADDRESS_591476] until they return to the study site at Visit 7 based on previous use (estimated to be 
approximately 3 batteries, 3 battery chargers and 66 cartridges assuming 3 per day ).  Subjects 
should be instructed to contact [CONTACT_461974][INVESTIGATOR_461937]. All test e-Vapor 
product dispensed and returned must be documented by [CONTACT_3452].  
Prior to dispensing, the study site will ensure the test e-Vapor product packaging is labelled to 
disclose, at minimum, the protocol number and unique subject identifiers, date it was dispensed, 
the statements of “For study use only, not for sale” and “Keep out of reach of children”.  
S
ubjects will be asked to bring back all used and unused products (cartridges) at each subsequent 
study visit. Study sites will perform accountability on the returned product.   
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 64 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591477] preferably between 
15 and 25oC (59 – 77 oF) and not to leave the product(s) in extreme conditions (e.g. in a car 
parked in the heat/cold, freezer, etc.). 
 Exhaled CO Measureme nt 11.[ADDRESS_591478] groups with exhaled CO measurements >[ADDRESS_591479] groups with 
exhaled CO measurements >[ADDRESS_591480] subjects on collection, storage, and returning the sample at the subsequent 
visit; subjects will be instructed that urine collection should occur at least 4 hours after the prior 
void. 
12.0 VISI
T 7, END OF STUDY (WEEK 12 / DAY 84 ± 3) 
Visi
t 7 should be arranged in the morning to accommodate fasting blood sampling. Subjects 
shoul
d be reminded to maintain their usual smoking/vapi[INVESTIGATOR_461938]; abstinence is not required. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 65 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Review of Inclusion / Exclusion Criteria 12.1
A brief assessment (medical/medication questionnaire) to affirm that the applicable inclusion and 
exclusion criteria/restrictions have not been violated since the Screening Visits will be 
performed. 
 Vital Signs 12.[ADDRESS_591481] used. 
 Body Weight and Body Mass Index 12.3
Weight (kg) will be recorded in indoor clothing without shoes. BMI will be calculated as weight 
(kg)/height (meters) squared (height measured at Screening will be used to calculate BMI ). 
 Spi[INVESTIGATOR_038] 12.4
All subjects will undergo spi[INVESTIGATOR_75037] (FEV1, FVC, and FEV1/FVC ratio) at the study site. 
Spi[INVESTIGATOR_235719] 2005 American Thoracic 
Society / European Respi[INVESTIGATOR_235720]. 
The spi[INVESTIGATOR_461925] a study specific spi[INVESTIGATOR_461926] a central 
vendor. The spi[INVESTIGATOR_461927]. Study site staff performing spi[INVESTIGATOR_461928]. The quality of the tests will be reviewed by a 
centralized over-reader. The spi[INVESTIGATOR_461939] e-Vapor product use and in sitting position. The subjects will be 
instructed on how to correctly perform spi[INVESTIGATOR_461940]. Spi[INVESTIGATOR_461941] a short-acting bronchodilator (albuterol). Following acceptable pre-
bronchodilator measurements, subjects will be administered 4 puffs from an albuterol metered-
dose 
inhaler at 30 second intervals (~360 µg total dose assuming 90 µg per puff) using a spacer 
and a 5-second breath hold after each puff. Post-bronchodilator measurements will be made 
approximately [ADDRESS_591482] albuterol puff. Spi[INVESTIGATOR_461942]. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 66 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Physical Examination (Symptom Driven) 12.[ADDRESS_591483]™ brochure or referral to the Quit Assist™ web site, which contains citations to a number 
of third-party information sources, including web sites, telephone resources, and other 
or
ganizations with additional information. 
 Clinical Laboratory Tests 12.7
All clinical laboratory tests will be conducted by a central laboratory facility accredited by [CONTACT_461973] (Clinical Laboratory Improvement Amendments of 
1988 [CLIA-88]) or at the clinic study site using CLIA-waived kits or procedures.  Values for the 
laboratory parameters are to be within the laboratory normal ranges or deemed not clinically 
significant in the opi[INVESTIGATOR_689]; clinically significant findings will be followed up as 
described for Adverse Events (Section 13.2). 
12.7.[ADDRESS_591484], blood urea nitrogen (BUN), alkaline phosphatase, total 
bilirubin, glucose, creatinine (at screening, creatinine clearance will be calculated using 
Cockcroft-Gault formula), total protein, uric acid, and albumin. 
12.7.[ADDRESS_591485] 8 hrs fasting, consisting of hemoglobin, hematocrit, 
red blood cell count (RBC), white blood cell count (WBC) with differential, and platelet count. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 67 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  12.7.3  Urinalysis 
Routine clinical urinalysis consisting of bilirubin, blood, glucose, ketones, leukocyte esterase, 
nitrite, pH, protein, specific gravity, and urobilinogen will be evaluated. Microscopic 
examination will be conducted if protein, leukocyte esterase, nitrite and/or blood are detected. 
Microscopic analysis will include RBC, WBC, casts, and bacteria.  
 Urine Pregnancy Test 12.[ADDRESS_591486]. 
 Review of Concomitant Medications 12.9
Any concomitant medications taken through the End of Study (or upon Early Termination) will 
be recorded. 
 12-Lead ECG 12.[ADDRESS_591487] be recorded in the eCRF. 
 Confirm Cigarette Brand / Photocopy Cigarette Pack 12.[ADDRESS_591488]’s regular brand of cigarettes (Control group) has 
not changed. If the regular brand has changed, the change will be documented and a photocopy 
of the pack made.  
 QGEN and TQOLIT questionnaires  12.13
S
ubjects will complete the QGEN and TQOLIT questionnaires (Appendix 2).  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 68 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Cough Questionnaire  12.14
Subjects will complete the Cough Questionnaire (Appendix 3 ). 
 T
est e-Vapor Product Collection  12.[ADDRESS_591489] and document all used and unused products (cartridges) at each 
study visit. The study site will perform accountability on the returned product. 
 Exh
aled CO Measurement 12.[ADDRESS_591490] urine void of the day, between 4:00am 
a
nd 7:00am, at least 4 hours after the prior void, in the dispensed container and bring it with 
them to the study site. Sample should be kept refrigerated until packed for transport to the study 
site. An ice pack should be placed in the package with the urine sample at the same time. Upon 
receipt, study staff should document the volume (mL) of the urine sample, status of the ice pack 
(present – not/or partially melted; present – fully melted; not present). 
 B
OPH and COHb Blood Sample Collection 12.19
Blood Collection for BOPH and COHb 
B
lood will be collected after overnight fasting (at least 8 hrs). 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 69 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Reasons of Use/Not-Use Test Product Questionnaire (Test group only) 12.20
S
ubjects will fill out the Reasons of Use/Not-Use Test Product Questionnaire (Appendix 6). 
 m
CEQ Questionnaire 12.21
S
ubjects will complete the appropriate mCEQ Questionnaire (Appendix 5a for Test groups, 5b 
for the Control group ). 
 End of Study Questionnaire 12.22
Subjects will fill out the End of Study Questionnaire Appendix 7a (Control  group) and Appendix 
7b (Test group) 
13.0 ADVERSE EVENTS 
The following is the definition for an AE: 
Any unfavorable or unintended sign (including an abnormal laboratory findinga), 
symptom, or diseaseb temporally associated with the use of a study products, 
whether or not  related to the study products.(ICH Guidelines, references 17 and 18 )  
a For this study, a laboratory AE is defined as an abnormal laboratory finding that is 
determined by [CONTACT_461976]. 
b ‘Disease’ includes a newly developed, worsened preexisting, recurring intermittent or 
intercurrent illness, injury, or condition. 
All AEs occurring during this clinical trial after the subject has signed the ICF document and 
after trial product use during Screening must be recorded in the eCRF, including the date and 
time of onset and outcome of each event. Events captured between ICF signing and prior to trial 
product use during Screening will be documented as baseline signs and symptoms in the eCRF. 
S
urgical procedures themselves are not AEs; they are therapeutic measures for conditions that 
require surgery. The condition for which the surgery is required may be an AE. Planned  surgery 
permitted by [CONTACT_49894](s) leading to this surgery are not AEs. 
No causal relationship with the study products or with the clinical study itself is implied by [CONTACT_461977] o
f the term “adverse event.” 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 70 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  The Investigator will review each event and rate each reported sign or symptom on a 3-point 
severity scale. The following definitions for rating severity  (ICH Guideline for Clinical Safety 
Data Management) will be used: 
Mild: The AE is easily tolerated and does not interfere with daily activity. 
Moderate: The AE interferes with daily activity, but the subject is still able to function. 
Severe: The AE is incapacitating and requires medical intervention. Note: This is not the 
same as “serious,” which is based on the outcome or action criteria usually 
associated with events that pose a threat to life or functioning.  
Each AE will also be assessed by [CONTACT_461978] (causality)  
using
 the following grades of certainty [the strength of a causal association may be revised as 
more information becomes available]: 
Not related:  Clearly and definitely due to extraneous cause (e.g., disease, environment) 
Unlikely :  a. Does not follow a probable temporal (i.e., time) sequence from use of study 
product. 
b. Does not follow a known pattern of response to the study product. 
c. Could plausibly have been produced by [CONTACT_423]’s clinical state/underlying 
disease or other drugs or chemicals the subject received. 
d. Doe s not reappear or worsen when the study product is re-administered. 
Possible: a. Follows a reasonable temporal (i.e., time) sequence from use of study product. 
b. Follows a known pattern of response to the study product. 
c. C
ould also have been produced by [CONTACT_423]’s clinical state/concurrent 
disease or other drugs or chemicals the subject received. 
Likely :  a. Follows a reasonable temporal (i.e., time) sequence from use of study product. 
b. Follows a known pattern of response to the study product. 
c. C
ould not readily have been produced by [CONTACT_423]’s clinical 
state/concurrent disease or other drugs or chemicals. 
d. F ollows a clinically reasonable response on withdrawal (dechallenge), i.e., 
disappears or decreases when the study product is stopped or reduced. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 71 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  e. Rechallenge information is not required to fulfill this definition. 
Definitely: a. Follows a reasonable temporal (i.e., time) sequence from use of study product. 
b. Follows a known pattern of response to the stduy product. 
c.  
Cannot be explained by [CONTACT_423]’s clinical state/concurrent disease or other 
drugs or chemicals. 
d. F ollows a clinically reasonable response on withdrawal (dechallenge), i.e., 
disappears or decreases when the study product is stopped or reduced. 
e. R
ecurs with re-exposure to study product (rechallenge). NOTE: Re-exposure 
of the subject is NOT required, but the “certainly/definitely related” category 
may only be used when recurrence is observed. 
 Serious Adverse Events 13.1
The following is the definition for  a serious adverse event (SAE):  
An 
SAE is any adverse study experience that results in any of the following 
outcomes:  
 de ath 
 a  life-threatening adverse study experiencea 
 in- patient hospi[INVESTIGATOR_1081] 
 a persistent or significant disability/incapacityb  
 a congenital anomaly/birth defect (ICH Guideline for Good Clinical Practice18).  
a “Life-threatening” means that the subject was at immediate risk of death at the time of the SAE; it does 
not refer to a SAE that hypothetically might have caused death if it were more severe. 
b “Persistent or significant disability/incapacity” means that there is a substantial disruption of 
a person’s ability to carry out normal life functions. 
Important medical events that may or may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, it 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. An example is allergic bronchospasm requiring intensive 
treatment in an emergency room or at home. 
All SAEs, whether or not  considered study product-related, must be reported by [CONTACT_461979] 24 hours of the study site’s learning of the SAE or, at the latest, on 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 72 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591491] inform ALCS within 24 hours of Medical 
Moni
tor’s notification.  The sponsor designated Medical Monitor to contact [CONTACT_461980]: 
Dr
. Kathy Smith 
Drug Safety Solutions 
Raleigh, NC [ZIP_CODE] [LOCATION_003] 
Phone: +[PHONE_9667] 
Fax: +[PHONE_9668] 
Email: [EMAIL_8863] 
Additionally, an SAE Report Form must be completed for all SAEs with as much information as 
is available and e-mailed or faxed within [ADDRESS_591492]. Information not available at the time of the 
initial report (e.g., end date, laboratory values) must be documented on a follow-up SAE form. 
SAEs will be reported for up to [ADDRESS_591493]’s completion of the study and 
followed for 30 days from onset or to a final outcome. Final outcome may be classified as 
resolved, improved, unchanged, worse, fatal, or unknown (lost to follow-up).  
 Adver
se Events / Serious Adverse Events Follow Up 13.[ADDRESS_591494] is still participating in the study. Final outcome may be classified as resolved, improved, 
unchanged, worse, fatal, or unknown (lost to follow-up). Where appropriate, medical tests and 
examinations will be performed to document the outcome of the AE. Appropriate supportive 
and/or definitive therapy will be administered as required. 
 Pregnancy 13.[ADDRESS_591495] use in the study will be documented on a pregnancy form, as a 
pr
otocol deviation, and reported in accordance with IRB guidance. Pregnancy itself is not a SAE. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 73 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591496] be reported by 
[CONTACT_461981] 24 hours of the study site’s learning 
of the pregnancy or, at the latest, on the following workday. The Medical Monitor must inform 
ALCS within 24 hours of Medical Monitor’s notification. The Investigator or designee will 
disconti
nue the pregnant subject from the study and will advise her to seek prenatal care and 
counseling from her primary care provider. The Investigator also will offer all participants the 
Quit Assist™ brochure or referral to the Quit Assist™ web site, which contains citations to a 
number
 of third-party information sources, including web sites, telephone resources and other 
or
ganizations with additional information. Advice given will be documented in the subject’s 
source document. 
The study site clinical staff will request the pregnant subject to notify the study site of the 
outcome of the pregnancy (i.e., birth, loss, or termination). To help ensure this, the study site 
clinical staff will follow up with the subject until the end of pregnancy, if in compliance with the 
study site’s standard operating procedures (SOPs) and with the subject’s consent. This request 
and the subject’s response will be documented in the subject’s source document. 
14.[ADDRESS_591497] SCREEN FAILURES 
Subjects may screen fail at Screening Visit 1, Part 1; Screening Visit 2, Part 2; and at Baseline , 
Visit 3. Subjects who screen fail at any point will be ineligible to continue with the study and 
will not be permitted to re-screen. Rechecks of borderline values are allowed at the Investigator’s 
discr
etion. Screen fail data to be captured will include subject demographics and reason(s) for 
screen failure. 
15.[ADDRESS_591498] if s/he feels this action is in the best interest of the subject. At 
the discretion of the Investigator, and in consultation with the Sponsor, a subject may be 
removed for failure to adhere to the requirements of the protocol. 
F
ollowing randomization on Day 1, if a subject terminates early from the study and has used test 
e-Vapor product provided by [CONTACT_1034], all used and unused test products (cartridges) should 
be
 returned if assigned to the Test group, and all  of the safety data normally required at the End 
of Study, Visit 7 (Week 12) should, if possible, be obtained. Subjects with AEs will be followed 
per Section 12. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 74 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591499] if s/he feels this action is in the 
best interest of the subject. 
Investigators are urged to enroll only those eligible subjects who are likely to complete the entire 
study and who are willing to comply with the requirements of the protocol. Subjects are 
discontinued from the study for any reason (including study completion) cannot re-enter. 
Subjects will be informed during the informed consent process that all biologic samples collected 
up to the point of withdrawal are intended for analysis but that they may notify the Investigator if 
they choose to withdraw consent for analysis of these samples prior to use. 
Subject Discontinuation Criteria 
Subject participation in this trial may be discontinued for any of the following reasons: 
 withdra wal of informed consent; 
 clinical AE, laboratory abnormality, or other medical condition (including pregnancy) 
that indicates to the Investigator that continued participation is not in the best interest of 
the subject; 
 fa ilure to meet Inclusion/Exclusion criteria; 
 nonc ompliance with study procedures, e.g.; 
o fa ilure to comply with daily CPD/cartridge recording requirements (>5 
consecutive days without recording). 
o failure to appear within required window for study visits 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 75 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  o eCO > 8 ppm on consecutive visits (Test groups only) 
 ter mination of the study by [CONTACT_1034], US Food and Drug Administration (FDA), or 
other regulatory authorities; or 
 lost  to follow-up.  
Protocol deviations should not lead to subject withdrawal unless they indicate a significant risk 
to the subject’s safety or jeopardize the scientific integrity of the study. Subject compliance with 
study product use and reporting is a critical component of this study; however, given the duration 
and ambulatory nature of the study 100% compliance is an unrealistic expectation. During each 
study visit, the study site staff will stress the importance of compliance with the study 
requirements and honestly reporting product use. Subjects who regularly fail to complete the 
daily product use entries or who have eCO measurements inconsistent with use of the study 
product assigned may be identified by [CONTACT_461982]. Disqualification for noncompliance with product use 
may occur with consultation with the Sponsor.  
Discontinuation Procedures 
If premature withdrawal from the study occurs for any reason, the Investigator must determine 
the primary reason and record this information in the case report form (eCRF). Subjects 
withdrawing or dismissed by [CONTACT_461983] (if assigned to one of the Test groups) and will undergo EOS 
safety procedures as feasible. 
If a subject becomes lost to follow-up, a reasonable effort will be made to contact [CONTACT_461984]- of-Study procedures. A reasonable effort is considered, at minimum, two 
attempts via phone (at least 1 day apart) followed by a certified letter to the subject’s last known 
address requesting their return to the study site for a safety evaluation and return of any study 
products. 
Subjects who are discontinued from the study for any reason after randomization will not be 
replaced. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 76 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  17.0 CLINICAL LABORATORY SAMPLES 
Values for the clinical laboratory parameters will be determined by a central laboratory facility 
accredited by [CONTACT_41685] (CLIA-88). Hematology, clinical 
chemistry, and urinalysis will be analyzed using standard clinical laboratory procedures.  
18.0 BIOANALYTICAL LABORATORY 
Biomarkers (BOEs and BOPHs) as noted below will be analyzed using validated analytical 
methods, and if applicable, with appropriate quality controls according to the FDA Guidance for 
Industry: Bioanalytical Method Validation (May, 2001)19 and in accordance with SOPs which 
are written to meet applicable portions of Good Laboratory Practice regulations (21 CFR Part 
58)18. 
Full sample collection methods, processing, storage, and shippi[INVESTIGATOR_461943].  An overview of sample requirements is as follows: 
Ur
ine markers: 
Biomarker  Number of 
Aliquots/Volume 
Required  Container Type  
Total NNAL / NNN  2 aliquots of 10 
mL each  UV shielded 
HDPP  
Creatinine  2 aliquots of 5 
mL each  HDPP  
8-epi-prostaglandin F 2α 2 aliquots of 5 
mL each  HDPP  
11-Dehydrothromboxane B 2 2 aliquots of 5 
mL each  HDPP  
Nicotine equivalents  2 aliquots of 5 
mL each  HDPP  
Bio-banking  Remaining 
volume after HDPE  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 77 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591500] presents the 
sa
mple and then stored at -20 ± 10°C until shipped to Celerion for analysis.   
B
lood markers: 
Biomarker  Volume and 
Collection Tube  Comments  
COHb  4 ml sodium 
heparin  store refrigerated 
until shipped  
sICAM  4 ml sodium 
heparin  centrifuge and 
freeze plasma at -
20°C  
WBC  [ADDRESS_591501]  allow to clot for 
30 minutes, 
centrifuge, and 
freeze serum at -
20°C 
Bio-banking  3.[ADDRESS_591502]  allow to clot for 
30 minutes, 
centrifuge, and 
freeze serum at -
20°C 
 
Approximately 8 5 mL of blood will be required for the planned assessments during the entire 
study. Details regarding the processing, storage, and shippi[INVESTIGATOR_461944]-banking 
samples will be provided in the sample handling guidance document prepared by [CONTACT_300237]. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 78 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   BOEs Urine (1st void of the day):  18.1
1) Tota
l NNAL in urine with creatinine adjusted (ng/g Cr) 
2) NNN in urine with creatinine adjusted (ng/g Cr) 
3) Nicotine equivalents (mg/g Cr) 
Samples of all BOE urine collections will be banked for potential future additional BOE and/or 
BOPH assessments 
 BOE Blood (after overnight fasting, at least 8 hrs): 18.2
1) C
OHb in whole blood (% sat) 
 BOPHs Urine (1st void of the day): 18.3
1) 8-epi-prostaglandin F 2α in urine with creatinine adjusted (ng/g Cr) 
2) 11-Dehydrothromboxane B 2 with creatinine adjusted (ng/g Cr) 
 B
OPHs Blood (after overnight fasting, at least 8 hrs): 18.4
1) W
BC in whole blood (103µ/L) 
2) HDL-C in serum (mg/dL) 
3) Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum (ng/mL) 
Samples of all BOPH blood collections will be banked for potential future BOPH and/or BOE 
assessments 
 Urine Creatinine (1st void of the day) 18.5
Ur
ine Creatinine levels (mg/mL) will also be measured for each urine sample and used to adjust 
for
 all urinary biomarkers. 
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 79 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591503] and the Control groups. 
Total NNAL, COHb, 11-Dehydrothromboxane B 2, 8-epi-prostaglandin F 2α WBC and HDL 
values from a previous PM[LOCATION_003] longitudinal study (Study #: EHCJLI/02/02)21 for the Electronic 
Heating Cigarette Smoking System and S-ICAM values from another source (Scott DA et. al. 
2000)[ADDRESS_591504], 3.5 % Type I error rate 
(a
djusted for multiplicity of detecting statistical significance in 5 out of the 7 biomarkers based 
on the Hailperion-Ruger approach), 80% power and a [ADDRESS_591505] group and 120 in the Control group are 
ne
eded. With a 15% dropout rate expected, a total of 450 subjects ([ADDRESS_591506] and 150 in 
Control groups) are needed at the randomization. The statistical power for each primary 
biomarker is provided below. 
 
Table 1. Approximate power for a preliminary sample size of test=120 
an
d control=120 subjects 
 
Biomarker  Cigarette Smoker 
(mean, SD)  Electrically Heated 
Cigarette Smoker or 
Quitter (mean, SD)  Power (%)  
Total NNAL (ng/g Cr)1 484.51 (187.50)  86.90 (134.19)  >85 
COHb (AUC (7-23h), % •hr)2 3.6 (18.1)  -70.7 (35.4)  >85 
8-Epi (ng/g Cr )3
 1320 (506.78)  1106.28 (456.74)  85 
11-Dehydro (mg/g Cr)1 1264.00 (533.58)  1011.53 (385.33)  >85 
WBC (X1,000/ul)2 -0.3 (1.3)  -1.1 (1.3)  >85 
HDL (mg/dl)2 0 (7.0)  5.0 (10.0)  >85 
S-ICAM (ng/ml)4 5 (66.0)  -66.1 (75.0)  >85 
 
1. Week 13 value21 
2. C
hange from baseline to Week 1321 
3. A
verage value of Week 8 and Week 17 due to potential bioanalytical data issue for Week 1320 
4. Scott D et. al. 200022.  
 
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 80 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Randomization 19.3
This is a multicent er clinical study and a c entral randomization will be used across the study 
sites. Randomization will be stratified by [CONTACT_547], age class and BMI classes:  
 BMI <25  BMI >25 BMI <25  BMI >25 
<45 years  Male  Male  Female  Female  
>45 years  Male  Male  Female  Female  
 
Further details will be provided in the Statistical Analysis Plan. 
 Criteria for Evaluation 19.4
19.4.1 Pr imary Endpoints 
The primary endpoints are the following biomarkers measured at Baseline (Day 1) and End of 
Study (Week 12): 
 W BC in whole blood (103 µg/L) 
 HD L-C in serum (mg/dL) 
 8-epi-prostaglandin F 2α in urine with creatinine adjusted (ng/g Cr) 
 11-dehydrothromboxane B 2 in urine with creatinine adjusted (ng/g Cr) 
 S oluble Intercellular Adhesion Molecule – 1 (sICAM-1) in serum (ng/mL) 
 Total NNAL in urine with creatinine adjusted (ng/g Cr) 
 COHb in whole blood (% sat) 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 81 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  19.4.2  Secondary Endpoint s  
The secondary endpoints are: 
1) Levels of selected biomarkers (same as the primary endpoints) and the following additional 
biomarkers measured at Baseline/Day 1 (Visit 3), Week 6 (Visit 5) and EOS (Visit 7 ): 
a) NNN in urine with creatinine adjusted (ng/g Cr) and exhaled CO. 
2) The 
average daily cigarettes smoked and Test Product use reported by [CONTACT_461985] 
2 through Week 6 and for Week 7 through EOS 
a) Test Products used per day, the number of  new cartridges  used, and average number of 
puffs taken (1 – 20 or >20) will be document through text message.  
b) The
 number of cigarettes smoker per day will be documented by [CONTACT_461986]. 
 
19.4.3 E xploratory Endpoints 
1) Assess changes in BOPHs and BOEs (same as in the primary objective) from Baseline to 
Week [ADDRESS_591507] e-Vapor Products   
2) F
EV1 (% predicted), FCV, and FEV1/FVC measured at Screening (Visit 2) and EOS 
3) Nic
otine Equivalents (Nicotine, Cotinine, Trans- 3'-Hydroxycotinine, Trans-3'- 
Hydroxycotinine-O-glucuronide, Nicotine-N-glucuronide, and Cotinine-N-glucuronide) (NE) 
in urine with creatinine adjustment (mg/g Cr), measured at Baseline/Day 1 (Visit 3), Week 6 
(V
isit 5) and EOS 
4) R
esponses (Score) to the QGEN and TQOLIT questionnaires and the Cough Questionnaire 
re
corded at Baseline/Day 1 (Visit 3), Week 6 (Visit 5) and EOS 
5) R
eponses to Reasons for Use and Not-use of Test Product at EOS and mCEQ questionnaires 
fr
om Baseline to EOS (Test group only) 
19.4.4  Clinical Safety Endpoint s  
Clinical safety analyses will be conducted on the clinical safety population. Clinical safety 
endpoints are: 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 82 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   AEs and SAEs  
 Blood pressure, ECG, vital signs, clinical chemistry, urinalysis, and hematology 
 Anal
yses Data Set  19.5
The intent to treat (ITT) population includes every subject who is randomized according to the 
randomization schedule. 
The modified intent to treat (MITT) population includes those subjects in the ITT population for 
which there is a baseline and at least one post-baseline biomarker measure.  
The clinical safety population (CSP) will consist of all subjects who are randomized and record 
at least one use of study products (i.e., conventional cigarettes or test e-Vapor products) after 
randomization. 
The
 per-protocol (PP) population is defined as a subset of the MITT population, which is 
c
omprised of subjects who completed the study without any major protocol violations, which are 
defined as: 
 C ontrol group: subjects who quit smoking 
 Te st groups: subjects who self-report use of > 10% of baseline CPD over the course of 
the study, subjects with an eCO > 8 ppm at Visits 4 – 7, or subjects whose NNN levels 
a
re consistent with smoking cigarettes 
The ITT and PP populations will be used for the analyses of subject demographics, baseline 
characteristics and tobacco product use. 
The MITT and PP populations will be used for the analyses of the primary endpoint, secondary 
endpoints of biomarkers, and exploratory endpoints. 
The
 CSP will be used for the analyses of AEs, vital signs, clinical laboratory findings and other 
study safety related variables. 
Deviations from the approved SAP will be reported in the final study report.  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 83 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  19.5.1  Demographics and Baseline Characteristics 
Demographic baseline characteristics collected at Screening will be summarized by [CONTACT_461987] (the number of non-missing values, the number of missing values 
mean, median, standard deviation [SD], minimum, maximum, 95% confidence interval) for 
continuous variables (e.g., BMI) and frequency counts for categorical variables (e.g., gender).  
19.5.[ADDRESS_591508] 
deviation, median, minimum and maximum will be provided for continuous variables, and 
counts and percentages for categorical variables 
All statistical analyses will be performed with SAS® software version 9.3 or above. 
[IP_ADDRESS] Pr imary Endpoint Analyses 
A 
linear mixed model for repeated measures (MMRM) analysis will be used for comparing each 
Test group to the Control group in the mean absolute change from Baseline to End of Study in 
each primary endpoint. In the model, study group, visit, and study group by [CONTACT_23259], 
gender, age class, race, and BMI class are the fixed effect factors. The baseline value of the 
re
sponse biomarker will be the fixed effect covariate and subject will be the random effect factor. 
The unstructured covariance structure will be used to model the covariance. The least-square 
mean difference, 95% confidence interval and p-value will be provided for the group difference. 
The analysis will be conducted on the MITT population. 
To assess the robustness of the primary MMRM analysis to the possible violation of the missing 
at random (MAR) assumption, the pattern mixture model based on the non-future dependent 
missing value restriction will be applied. In addition, a supportive analysis based on the per-
protocol ( PP) population will also be conducted. 
[IP_ADDRESS] S econdary Endpoint Analyses 
 The  MMRM as used for the primary endpoints will be used to test the differences in the 
mean absolute change from Baseline to Week 6 for the selected biomarkers (WBCs, HDL-C, 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 84 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  COHb, total NNAL, 8-epi-prostaglandin F 2α, 11-Dehydrothromboxane B 2 and sICAM-1) 
between each Test group and the Control group.  
 De scriptive statistics (the number of subjects with non-missing data, number of subjects with 
missing data, mean, standard deviation, median, minimum and maximum) will be used to 
summarize the average cigarettes per day and daily e- Vapor cartridge consumption amount 
by [CONTACT_461988] 2 through Week 6 and from Week 7 through EOS. Frequency tables 
will also be used to summarize the proportions of change categories (reduce, no change, 
increase or percentage) from baseline to end of study for each study group.  
 A frequency table (n and %) will be used to summarize use of other tobacco products, eCO 
and NNN for assessment of compliance and noncompliance for each study group 
[IP_ADDRESS] E xploratory Endpoints Analyses 
The MMRM approach will be used to provide the estimates for: 
 c hanges in BOPHs and BOEs from Baseline to Week 6 and EOS in two subgroups that 
use different flavored e-Vapor products  
 c hanges in forced expi[INVESTIGATOR_104763] (FEV 1), forced vital capacity 
(FVC), and FEV 1/F VC ratios from Baseline to EOS in the Test and Control groups 
 c hanges in urine nicotine equivalents ( NE) from Baseline to Week [ADDRESS_591509] and Control groups 
 c hanges in the QGEN and TQOLIT questionnaires and the Cough Questionnaire from 
Baseline to EOS in  the Test and Control groups 
 Dealing with Missing Data 19.6
I
n general, missing data will remain as missing in data description, i.e., no attempt will be made 
to impute missing values and only observed values will be used in descriptive statistics. For the 
primary endpoint analyses, missing data will be handled using the MMRM. Likewise, for all 
other endpoints using the MMRM analysis, missing data will be handled by [CONTACT_10994]. For 
sensitivity analyses using ANCOVA models, missing data will be imputed using multiple 
imputation with pattern-mixture model. For secondary or exploratory analyses using the missing 
data will not be imputed. Details about missing data imputation for the primary endpoints will be 
provided i n the statistical analysis plan. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 85 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   Subgroup Analysis 19.7
A subgroup analysis will be conducted for change from Baseline to End of Study in the primary 
biomarkers for those covariates including gender, age class, race and BMI that proved to be 
significant in the MMRM model.  
All su
bgroup analyses are exploratory in nature. 
20.0 DATA MANAGEMENT 
Every effort will be made to ensure that data management practices adhere to ethical and 
scientific quality standards of clinical data management procedures. The sponsor will contrac t 
with Celerion to manage the data for this investigation. Details about the data management 
activities will be specified in the Data Management Plan (DMP). 
 Database Design and Creation 20.1
An appropriate database will be designed and created within a validated Clinical Data 
Management System (CDMS). Electric data capture will be used for this study and eCRFs will 
be developed according to the study protocol specifications. Clinical and analytical laboratory 
data will be collected external to CDMS as external data files. 
 Data Coding 20.2
Upon completion of the eCRF data entry by [CONTACT_3452], a secondary clinical review will be 
conducted by [CONTACT_300237]. Adverse events and medical history coding will be undertaken using 
MedDRA®. Concomitant medications coding will be undertaken using WHO-DD. Each 
dictionar
y version will remain the same throughout the trial. 
 Data Entry and Verification 20.3
Data will be entered directly or transmitted from other sources by [CONTACT_461989]’s staff into the eCRF. Ancillary data received from clinical and analytical 
laboratories (clinical laboratory results) will be integrated into the Clinical Data Interchange 
Standards Consortium study data tabulation model datasets. 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 86 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591510] the eCRF. 
Inconsistencies that arise from these edit checks will be resolved with the Investigator or 
designee. 
 Database Lock 20.6
On study completion, after data entry is complete, the data has been pronounced clean, and the 
Principal Investigator [INVESTIGATOR_461945], the database will be 
locked and final write access will be removed. 
The final transfer of all study data (without subject personally identifying information) to the 
study sponsor will be in SAS format. 
21.[ADDRESS_591511] and visit the Investigator as necessary, 
and he/she will be allowed, upon request, to inspect and verify various records of the study (e.g., 
source documents, ICFs, eCRFs) in a manner consistent with GCP and all other applicable state 
and federal laws. 
It will be the monitor or designee’s responsibility to review the eCRFs to verify the adherence to 
the protocol and the completeness, consistency, and accuracy of the data being entered. The 
monitor will verify that each subject has consented in writing. Where the terms of the informed 
consent, GCP, and all other applicable state and federal laws permit, the monitor should have 
access to laboratory test reports and other subject records needed to verify the entries in the 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 87 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  eCRF. The Investigator (or his/her designee) agrees to co-operate with the monitor to ensure that 
any problems detected in the course of these reviews are resolved. 
22.[ADDRESS_591512] whether or not he/she has completed the 
study. All eCRFs will be reviewed and signed by [CONTACT_737].  
 S
tudy Report 22.[ADDRESS_591513] names, initials, date of birth (except year), or 
other personal identifiers.[ADDRESS_591514] their medical records to verify the 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 88 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591515] confidence and in accordance with local data protection laws. 
 Responsibility of the Investigator 23.2
The Investigator is responsible for ensuring that the clinical study is performed in accordance 
with the Declaration of Helsinki and in a manner consistent with the ICH Guideline for GCP and 
the corresponding section of the US CFR governing Protection of Human Subjects (Title 21 CFR 
Part 50)15, and Institutional Review Boards (Title 21 CFR Part 56)17.  
The Investigator should ensure that all persons assisting with the study are qualified for the 
duties assigned, adequately informed and trained about the protocol and amendments to the 
protocol, the test e-Vapor products, and their study-related duties and functions. 
The
 Investigator will maintain a list, including signatures, of sub-investigators and other 
appropriately qualified persons to whom significant study-related duties are delegated. Any 
personnel change in this list during the course of the study will be documented. All study related 
training will be documented. 
 Procedure for Amendments to Protocol 23.3
No deviations from this protocol will be permitted, except in a medical emergency, without the 
approval of the Sponsor. If agreement is reached concerning the need for modification, this 
agreement will be made in a formal amendment to the protocol. 
All revisions and/or amendments to the protocol must be approved in writing by [CONTACT_1201], if 
applicable. 
All persons who are affected by [CONTACT_461990]. 
 Institutional Review Board 23.[ADDRESS_591516] recruitment 
materials/process (e.g., advertisements), and any other written information that will be provided 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 89 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591517] also be submitted and receive 
approval from the IRB prior to implementation at the study site. The IRB approval should be 
obtaine
d in writing, clearly identifying the trial, the documents reviewed, and the date of the 
review. 
The Investigator or Sponsor should also provide the IRB with a copy of other information 
according to regulatory requirements or Institution procedures. 
 Termination of Study 23.5
The Sponsor reserves the right to discontinue this study at any time. The Investigator, in 
collaboration with the Sponsor, reserves the right to discontinue the study for safety reasons at 
any time. 
 Study Records Retention 23.6
Investigator-specific essential documents and all primary data, or copi[INVESTIGATOR_20583] (e.g., eCRFs, 
laboratory records, data sheets, correspondence, photographs, computer records, photocopi[INVESTIGATOR_461946]-issued ID to verify subject age), which are a result of the original observations and 
activities of the study and are necessary for the reconstruction and evaluation of any study report 
will be retained in the investigative study site’s archives for a minimum  of 20 years after the 
completion or termination of the study. It is the responsibility of the Sponsor to inform the 
Investigator as to when these documents no longer need to be retained. The study report and final 
da
tabase will be retained in CRO NAME’s archives for a minimum  of 20 years after the 
completion or termination of the study and will be available for inspection at any time by [CONTACT_429]. At completion of the study (i.e., at issuance of final study report), the final database 
will be transferred to the Sponsor. Subject names, initials, date of birth (except year), and other 
personal identifiers (including photocopi[INVESTIGATOR_461947]) will be redacted from this 
data transfer file; any such information removed will be documented at the time of transfer.  
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 90 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  24.0 REFERENCES  
1. F inal Rule: Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and 
Cosmetic Act, as Amended by [CONTACT_461991]; 
Restrictions on the Sale and Distribution of Tobacco Products and Required Warning 
Statements for Tobacco Products. 81 Fed. Reg. [ZIP_CODE] (May 5, 2016) 
2. R oyal College of Physicians. Nicotine without smoke: Tobacco harm reduction. London: 
RCP, 2016. 
3. R odgman A, Smith CJ, Perfetti TA. The composition of cigarette smoke: a retrospective, 
with emphasis on polycyclic components. Hum Exp Toxicol. 2000;19 (10):573-[ADDRESS_591518]-Pi[INVESTIGATOR_34025] K, et al. Evaluation of biomarkers of exposure to selected 
cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-
term and long-term clinical studies. Nicotine Tob Res. 2008;10(12):1761-1772. doi: 
10.1080/14622200802443718 
5. Flora JW, Meruva N, Huang CB, et al. Characterization of potential impurities and 
degradation products in electronic cigarette formulations and aerosols. Regul Toxicol 
Pharmacol. 2016;74:1-11. doi: 10.1016/j.yrtph.2015.11.[ADDRESS_591519] Applications for Electronic Nicotine Delivery Systems draft 
guidance (May 2016) ICH. S2(R1) Genotoxicity Testing and Data Interpretation for 
Pharmaceuticals Inten ded for Human Use. 2012.  
8. OECD. (2014) Test No. 487: In Vitro Mammalian Cell Micronucleus Test, OECD 
Guidelines for the Testing of Chemicals, Section 4. 
9. OECD. (2010) Test No. 129: Guidance document on using cytotoxicity tests to estimate 
starting doses for acute oral systematic toxicity tests. 
10. OECD. (1997) Test No. 471: Bacterial reverse mutation test.  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 91 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  11. OECD (2014). Test No. 474: Mammalian Erythrocyte MN Test. 
12. OECD ( 2014).  Test No. 489: In Vivo Mammalian Alkaline Comet Assay. 
13. W erely MS, Kirkpatrick DJ, Oldham MJ, Jerome AM, Langston TB, Lilly, PD, Smith DC 
and McKinney WJ. 2016. Toxicological assessment of a prototype e-cigaret device and 
three flavor formulations: a 90-day inhalation study in rats. Inhal Toxicol 28(1): 22-38. 
14. I ARC Monographs on the Evaluation of Carcinogenic Risks to Humans. List of 
classifications, volumes 1-117. 
http://monographs.iarc.fr/ENG/Classification/latest_classif.php  
15. United St ates Department of Labor. Occupational Safety and Health Administration. 
Chemical Sampling Information. Glycidol. 
https://www.osha.gov/dts/chemicalsampling/data/CH_243700.html 
16. U.S.Department of Health and Human Services. The Health Consequences of  Smoking: 50 
Years of Progress. A Report of the Surgeon General.  Atlanta: U.S. Department of Health 
and Human Services, Centers for Disease Control and Prevention, National Center for 
Chronic Disease Prevention and Health Promotion, Office on Smoking and H ealth. , 2014.  
17. ICH Guideline for Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting (E2A). Federal Register. Vol. 60, March 1, 1995, p. [ZIP_CODE]. 
18. ICH Guideline for Good Clinical Practice: Consolidated Guidance (E6). Federal Register. 
Vol. 62, May 9, 1997, p. [ZIP_CODE]. 
19. FDA Guidance for Industry, Bioanalytical Method Validation. 2001 May. 
http://www.fda.gov/cder/guidance/4252fnl.pdf  
20. Code of Federal Regulations Title 21, Part 58, Good Laboratory Practice for Nonclinical 
L
aboratory Studies 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58  
21. Roethig H, S Feng, Q Liang, J Liu, A. Rees, and B. Zedler. 2008. A 12-Month, 
Randomized, Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 92 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  Adult Smokers Switching From Conventional Cigarettes to a Second-Generation 
Electrically Heated Cigarette Smoking System. J Clin Pharmacol. 48: [ADDRESS_591520] PY, Gustavsson G. 
2000. Dramatic decline in circulating intercellular adhesion molecule-1 concentration on 
quitting tobacco smoking. Blood Cells, Molecules, and Diseases 26(3):255-258.  
23. U.S. Department of Health and Human Services. HIPAA Privacy Rule. Information for 
Researchers. De-identifying Protected Health Information Under the Privacy Rule. 
Available online at http://privacyruleandresearch.nih.gov/pr_08.asp#8a. Last accessed 
August 30, 2011.   
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 93 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  APPENDECES 
Appendix 1: Demographics and Tobacco Use History Questionnaires 
A01.1 Demographic Information 
 
 
1. What is your date of birth? 
 
 _____________________ 
 
2. What is your gender? 
 
 Male 
 Female 
 
3. Are you Hispanic or Latino? 
 
 Yes 
 No 
 
4. Which one of these groups would you say best describes your race? 
 
 White/Caucasian 
 Black/African American 
 Asian 
 Native Hawaiian or other Pacific Islander 
 American Indian or Alaska Native 
 Other (SPECIFY): _________________________________   
 
5. What was your annual household income from all sources over the past year? 
 
 Under $20,000 
 $20,000 - $29,999 
 $30,000 - $39,999 
 $40,000 - $49,999 
 $50,000 - $59,999 
 $60,000 - $74,999 
 $75,000 - $99,999 
 $100,000 - $149,999 
 $150,000 and over  
 I do not wish to answer 
 
6. What is the highest grade or year of school you completed? 
 
 Never attended school or only attended kindergarten 
 Grades 1 through 8 (elementary) 
 Grades 9 through 11 (some high school) 
 Grade 12 or GED (high school graduate) 
 College 1 year to 3 years (some college or technical school) 
 College 4 years or more (college graduate) 
 Postgraduate/masters/doctorate/law/MD 
 Other 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 94 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016   I do not wish to answer 
 
7. Are you currently…? 
 
 Employed for wages 
 Self-employed 
 Out of work for more than 1 year 
 Out of work for less than 1 year 
 A homemaker 
 A student 
 Retired 
 Unable to work 
 I do not wish to answer 
 
8. If you work outside of the home, what setting best describes your place of work…(Please check one) 
 Office 
 Manufacturing 
 Food Service 
 Transportation 
 Construction 
 Other  
 
9. Have you ever served on active duty in the U.S. Armed Forces, military Reserves, or National Guard? Active 
duty does not include training in the Reserves or National Guard, but DOES include activation, for example, 
for the Persian Gulf War. [Select only one answer]  
 
 Yes, now on active duty 
 Yes, on active duty in the last 12 months but not now 
 Yes, on active duty in the past, but not in the last 12 months 
 No, not on active duty but training for Reserves or National Guard only 
 No, never served in the military 
 I do not wish to answer 
 
10. What is your marital status? 
 
 Single 
 Married/living with significant other 
 Separated/divorced/widowed 
 I do not wish to answer 
 
11. Do you think of yourself as….? 
 
 Heterosexual or straight 
 Lesbian or gay 
 Bisexual 
 Transgender 
 Something else 
 Don’t know/not sure 
 I do not wish to answer 
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 95 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  A01.2 Tobacco/Nicotine Use History 
 
 
1. How long have you smoked cigarettes on a CONSISTENT BASIS? By [CONTACT_461992]. Examples might include using the product every day, a 
few times a week, only on the weekend, etc. 
If less than [ADDRESS_591521] 12 months did you smoke cigarettes every day, some days, rarely, or not at all? 
 Every Day 
 Some Days 
 Rarely 
 Not At All  
3. During the past 12 months, how many cigarettes did you smoke per day, on average? 
Number of Cigarettes Per Day: _______ [Please provide a single number]  
 
4. How soon after you wake up do you smoke your first cigarette? 
  Within 5 minutes 
  6 – 30 minutes 
  31 – 60 minutes 
  After [ADDRESS_591522] you stopped smoking for more than one day BECAUSE YOU WERE 
TRYING TO QUIT SMOKING? 
 
 Yes  
 No  
 
6. Are you planning to quit smoking cigarettes in the next 30 days? 
 
 Yes  
 No  
 
 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 96 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  7. There are many different types of tobacco products. Please read the description on the left, and then indicate 
with check marks the tobacco products that (1) you have ever used, even once, and (2) now use every day, 
some days, rarely or not at all. 
 
 
Tobacco Product  Check the box 
next to each 
tobacco product 
that you have 
EVER  used, even 
once  Of the tobacc o products that you 
have ever used, check whether 
you use d the product  in the past 
30 days  
Every 
day Some 
days  Rarely  Not 
at all  
ELECTRONIC CIGARETTES or E-VAPOR  products (“e -
cigarettes”) An electronic cigarette (e -cigarette) is a 
battery -powered device that is puffed like a cigarette      
 
BIDIS OR KRETEKS  
Popular in other parts of the world.  Bidis are small hand -rolled 
cigarettes.  Kreteks are clove -flavored cigarettes.  An example of a 
kretek brand is  DJARUM BLACK      
 
PREMIUM CIGARS  
Come in different sizes and shapes. Some examples of premium 
cigar brands are MACANUDO , ARTURO FUENTE  AND 
ROMEO Y JULIETA .     
 
LARGE CIGARS  
Not premium cigars; generally wider and longer than cigarillos.  
PHILLIES BLUNT  cigars is  an example of a large cigar brand.      
 
CIGARILLOS (INCLUDING BLACK & MILD)  
Generally narrower and shorter than premium cigars; they may 
come with plastic or wooden tips.  BLACK & MILD  is an example 
of a cigarillo brand.  Other examples include SWISHER SWEETS  
and DUTCH MASTERS .     
 
LITTLE CIGARS  
Look similar to cigarettes, except they are brown and have a filter 
like a cigarette.  Some examples of little filtered cigar brands are  
WINCHESTER , CAPTAIN BLACK  and WRANGLER .     
 
CHEWING TOBACCO  
Coarsely shredded and sold in pocket -sized packs of loose 
tobacco leaves or in a “plug” or “twist” form.  Brands include  RED 
MAN , LEVI GARRETT  and BEECH -NUT.     
 
SNUFF (DIP)  
Finely ground form of tobacco that is usually sold in a tin.  Brands 
include  GRIZZLY , COPENHAGEN  and SKOAL .     
 
SNUS  
Spi[INVESTIGATOR_461948] a tin.  CAMEL SNUS  is an example of a snus 
brand.      
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 97 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591523] 
30 days  
Every 
day Some 
days  Rarely  Not 
at all  
OTHER NEW ORAL TOBACCO OR  
TOBACCO -DERIVED NICOTINE PRODUCTS  
Meant to be chewed or dissolved in the mouth.  Examples include  
CAMEL ORBS , STRIPS , or STICKS ; ARIVA  or STONEWALL  
and VERVE DISCS .     
 
HOOKAH  
Or “narghile” pi[INVESTIGATOR_5836], is a type of water pi[INVESTIGATOR_461949].      
 
PI[CONTACT_153056]  
A regular smoking pi[INVESTIGATOR_461950] a bowl for tobacco, stem and 
mouthpi[INVESTIGATOR_13959].      
 
 
 
8. Have you used a nicotine patch, gum, inhaler, nasal spray or lozenge in the past 30 days? 
 
 Yes  
 No  
 
 
 
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 98 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 QGEN & TQOLIT  
 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 99 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
  

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 100 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
  

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 101 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
  
 

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 102 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
  
  

Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 103 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 Appendix 3: Cough Questionnaire 
I. Did you have a cough in the past 30 days? 
1. Yes – PROCEED TO QUESTION II. 
2. No – STOP. DO NOT ANSWER THE REST OF THE QUESTIONS. 
 
II. How long have you had the cough? (provide a number)  
1. ____ Days 
2. ____ Weeks 
3. ____ Months 
4. ____ Years 
 
III. When does the cough occur? (choose one)  
1. Middle of the night 
2. Daytime 
3. Anytime 
 
IV. Do you have a cough that comes mainly from your chest and NOT from your throat  
1. Yes, cough mainly comes from my chest  
2. No 
 
V. Do you cough up phlegm?  
1. Never 
2. Seldom 
3. Sometimes 
4. Often 
5. Always 
 
VI. Do you cough more than the average person?  
1. Yes 
2. No 
 
VII. Have you taken medications for your cough?  
1. Yes 
2. No 
 
VIII. Have you sought the help of a health care provider to treat your cough?  
1. Yes 
2. No 
 
IX. In the last 24-hours, has your cough disturbed your sleep?  
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 104 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591524] you had coughing bouts?  
1. All the time (continuously) 
2. Most times of during the day 
3. Several times during the day 
4. Some times during the day 
5. Occasionally through the day 
6. Rarely 
7. None 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 105 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 Appendix 4: Test e-Vapor Product Assessment Questionnaire 
 
Now that you have tried the e-Vapor product s, how likely are you to be willing and able to use this 
product to replace all  of your conventional cigarettes for 3 months  during the study? (CHECK ONE 
RESPONSE ONLY) 
 
A.  ____ Definitely  
B.  ____ Probably  
C.  ____ Might or might not  
D.  ____ Probably not     
E.  ____ Definitely not 
  
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 106 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 Appendix 5a : mCEQ-E Questionnaire (Test groups only) 
 
Please mark the number that best represents how using the test e-Vapor product made you 
fe
el (1—not at all, 2—very little, 3—a little, 4—moderately, 5—a lot, 6—quite a lot, 7—
e
xtremely). 
---------------------------------------------------------------------------------------------------------------- 
1. Was using the test e-Vapor product satisfying?  ____  (1….7)    
2. Did the 
test e-Vapor product taste good?   ____  (1….7) 
3. Did 
you enjoy the sensations in your throat and chest?   ____  (1….7) 
4. Did using the test e-Vapor product calm you down?  ____ (1….7) 
5. Did using
 the test e-Vapor product make you feel more awake?  ____ (1….7) 
6. Did using
 the test e-Vapor product make you feel less irritable?  ____ (1….7) 
7. Did using
 the test e-Vapor product help you concentrate?  ____ (1….7) 
8. Did using
 the test e-Vapor product reduce your hunger for food?  ____ (1….7) 
9. Did using
 the test e-Vapor product make you dizzy?  ____ (1….7) 
10. Did using
 the test e-Vapor product make you nauseous?  ____ (1….7) 
11. Did usi
ng the test e-Vapor product immediately relieve your craving for a cigarette?  
____ (1….7) 
12. Did you enjoy using the test e-Vapor product? ____ (1….7) 
 
A
ppendix 5b: mCEQ-C Questionnaire (Both Groups at Baseline, Control 
group only at EOS) 
 
Please mark the number that best represents how using the test e-Vapor product made you 
fe
el (1—not at all, 2—very little, 3—a little, 4—moderately, 5—a lot, 6—quite a lot, 7—
e
xtremely). 
---------------------------------------------------------------------------------------------------------------- 
1. Is smoking cigarettes satisfying?  ____  (1….7)    
2. Doe
s smoking cigarettes taste good?   ____  (1….7) 
3. Do 
you enjoy the sensations in your throat and chest?   ____  (1….7) 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 107 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 4. Does smoking cigarettes calm you down?  ____ (1….7) 
5. Does sm
oking cigarettes make you feel more awake?  ____ (1….7) 
6. Does sm
oking cigarettes make you feel less irritable?  ____ (1….7) 
7. Does sm
oking cigarettes help you concentrate?  ____ (1….7) 
8. Does sm
oking cigarettes reduce your hunger for food?  ____ (1….7) 
9. Does sm
oking cigarettes make you dizzy?  ____ (1….7) 
10. Does sm
oking cigarettes make you nauseous?  ____ (1….7) 
11. Does sm
oking cigarettes immediately relieve your craving for a cigarette?  ____ (1….7) 
12. Do you enjoy smoking cigarettes? ____ (1….7) 
 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 108 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 Appendix 6: Reasons of Use/Not-Use Test Product Questionnaire (Test 
group only) 
 
1. How likely are you to use e-cigarettes exclusively in the next 30 days? 
Strongly Likely     Quite Likely   Somewhat Likely Neutral/Neither  
Stro
ngly Unlikely   Quite Unlikely        Somewhat Unlikely 
 
2.
 How likely would you be to use the test product exclusively in the next 30 days? 
Strongly Likely     Quite Likely   Somewhat Likely Neutral/Neither  
Stro
ngly Unlikely   Quite Unlikely        Somewhat Unlikely 
 
3. Why would you use the test product NOW? (CLICK ALL THAT APPLY) 
 
Smoking/Other Tobacco-Related Reasons 
To satisfy my nicotine cravings .........................................................................................................................  1 
To help cut back or quit smoking/using other tobacco products ....................................................................... 1 
To help prevent relapse/return to smoking/using other tobacco products .........................................................  1 
To use in places where I cannot or should not smoke/use other  tobacco products ........................................... 1 
To not smell like smoke  ................................................................................................................................  1 
To not bother other people with smoke/smell of cigarettes/other tobacco products .......................................... 1 
It might be less harmful than cigarettes/other tobacco produc ts ........................................................................ 1 
To reduce negative smoking related health symptoms ...................................................................................... [ADDRESS_591525] to quit using tobacco products altogether ......................................................................... 1 
It might be less harmful for other people around me .........................................................................................  1 
More affordable than cigarettes/other tobacco products .................................................................................... 1 
General Reasons 
Curiosity  ................................................................................................................................  1 
Offered/given/used by a friend/family member ................................................................................................ . 1 
Enjoy the taste  ................................................................................................................................  1 
Enjoy the effects  ................................................................................................................................  1 
Advertising or promotion (e.g., magazine ad, in-store, coupon) ....................................................................... 1 
To meet other people or be part of a larger group .............................................................................................  1  
To suppress appetite for food ............................................................................................................................  1   
Other reason  ...................................................................................................................................... 1 
Don’t know (SP)  ...................................................................................................................................... 1 
  
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 109 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date 10 November 2016  
 Appendix 7a: End of Study Questionnaire (Control group only) 
 
The following questions are to help in the interpretation of this study and design of future studies, please be 
completely honest.  Your answers will not affect your compensation or eligibility for future studies in any way. 
 
1. When you collected your 1st void of the day urine collections, were you able to always collect the first 
void of the day at least 4 hours since the prior void? 
 
_____Yes 
_____No 
 
2. Were you able to continue to smoke your average cigarettes per day every day over the past 3 months? 
 
_____Every day 
_____Most days 
_____Some days 
_____Rarely  
_____Not at all 
 
3. Did you smoke more than your average cigarettes per day over the past 3 months? 
 
_____Every day 
_____Most days 
_____Some days 
_____Rarely  
_____Not at all 
 
4. Did you smoke less than your average cigarettes per day over the past 3 months? 
 
_____Every day 
_____Most days 
_____Some days 
_____Rarely  
_____Not at all 
 
 
5. Were there any days when you did not smoke at all? 
 
_____Yes: If yes, how many days ____________ (please provide a single number) 
_____No 
 
 
 
 
Appendix 7b: End of Study Questionnaire (Test groups only) 
 
The following questions are to help in the interpretation of this study and design of future studies, please be 
completely honest.  Your answers will not  affect your compensation or eligibility for future studies in any way. 
 
1. When you collected your 1st void of the day urine collections, were you able to always collect the first 
void of the day at least 4 hours after the prior void? 
 
_____Yes 
Altria Client Services Study No. ALCS- RA-16-06-EV  
 
 
Page 110 of 110 HIGHLY CONFIDENTIAL 
VERSION: Final Date [ADDRESS_591526]? 
 
_____Yes: If yes, on how many days? ____________ (please provide a single number) 
  On the days that you smoked what was the average number of cigarettes?_____________ 
_____No 
 
3. Did you use the test e-Vapor product… 
 
_____Every day 
_____Most days 
_____Some days 
_____Rarely  
_____Not at all 
 
 